Protein	B-protein
kinase	I-protein
C	I-protein
regulates	O
Fas	B-protein
(	O
CD95/APO-1	B-protein
)	O
expression	O
.	O

Fas	B-protein
(	O
CD95/APO-1	B-protein
)	O
is	O
a	O
transmembrane	B-protein
protein	I-protein
of	O
the	O
TNF/neuron	B-protein
growth	I-protein
factor	I-protein
receptor	I-protein
family	I-protein
.	O

Ligation	O
of	O
Fas	B-protein
by	O
specific	B-protein
Abs	I-protein
or	O
Fas	B-protein
ligand	I-protein
(	O
FasL/CD95	B-protein
ligand	I-protein
)	O
induces	O
rapid	O
apoptotic	O
cell	O
death	O
in	O
a	O
variety	O
of	O
cell	O
types	O
.	O

Despite	O
progress	O
in	O
understanding	O
the	O
death	O
signals	O
transduced	O
from	O
Fas	B-protein
,	O
very	O
little	O
is	O
known	O
with	O
regard	O
to	O
the	O
mechanisms	O
by	O
which	O
Fas	B-protein
expression	O
is	O
regulated	O
.	O

Using	O
our	O
previously	O
established	O
murine	B-cell_line
T	I-cell_line
cell	I-cell_line
hybridoma	I-cell_line
model	I-cell_line
A1.1	B-cell_line
,	O
we	O
show	O
that	O
specific	O
protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
inhibitors	O
could	O
block	O
activation-induced	O
Fas	B-protein
expression	O
and	O
apoptosis	O
.	O

The	O
activation	O
of	O
PKC	B-protein
with	O
PMA	O
or	O
1-oleoyl-2-acetyl-sn-glycerol	O
could	O
mimic	O
the	O
TCR	B-protein
signal	O
by	O
inducing	O
the	O
expression	O
of	O
Fas	B-protein
but	O
not	O
FasL	O
.	O

PKC	B-protein
-dependent	O
Fas	B-protein
expression	O
was	O
also	O
observed	O
in	O
several	O
murine	B-cell_line
and	I-cell_line
human	I-cell_line
tumor	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

Since	O
the	O
inhibition	O
of	O
Ca2+	O
redistribution	O
by	O
an	O
inhibitor	O
of	O
intracellular	O
Ca2+	O
mobilization	O
,	O
8-	O
(	O
diethylamino	O
)	O
-octyl-3	O
,	O
4	O
,	O
5-trimethoxybenzoate	O
hydrochloride	O
,	O
inhibited	O
TCR-induced	B-protein
FasL	I-protein
but	O
not	O
Fas	B-protein
,	O
the	O
expression	O
of	O
Fas	B-protein
appears	O
to	O
be	O
independent	O
of	O
Ca2+	O
mobilization	O
.	O

Significantly	O
,	O
expression	O
of	O
the	O
newly	O
identified	O
Fas-regulatory	B-DNA
gene	I-DNA
,	O
TDAG51	B-DNA
,	O
was	O
found	O
to	O
be	O
dependent	O
upon	O
the	O
activity	O
of	O
PKC	B-protein
.	O

PKC	B-protein
activation	O
only	O
induced	O
Fas	B-protein
expression	O
in	O
cells	O
expressing	O
wild-type	O
TDAG51	B-DNA
.	O

Thus	O
,	O
Fas	B-protein
expression	O
is	O
likely	O
mediated	O
by	O
PKC	B-protein
through	O
TDAG51	B-DNA
.	O

MR	NULL
a-PD-	NULL
}	NULL
,	NULL
a-PD-Li	NULL
)	NULL
o-4-1f	NULL
*in	NULL
VIVO	NULL
(	NULL
RESEARCH	NULL
*	NULL
FJiscoveP	NULL
More	NULL
#	NULL
m	NULL
meJournal	NULL
of	NULL
Protein	NULL
Kinase	NULL
C	NULL
Regulates	NULL
Fas	NULL
egg-Immunology	NULL
(	NULL
CD95/APO-1	NULL
)	NULL
Expression	NULL
Ruoxiang	NULL
Wang	NULL
,	NULL
Liying	NULL
Zhang	NULL
,	NULL
Deling	NULL
Yin	NULL
,	NULL
R.	NULL
Allan	NULL
Mufson	NULL
This	NULL
information	NULL
is	NULL
current	NULL
as	NULL
__	NULL
``	NULL
``	NULL
C	NULL
*	NULL
``	NULL
08°	NULL
``	NULL
of	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

J	NULL
Immunol	NULL
1998	NULL
;	NULL
161:2201-2207	NULL
;	NULL
;	NULL
http	NULL
:	NULL
//www	NULL
.jimmunol.org/content/161/5/2201	NULL
References	NULL
_	NULL
This	NULL
article	NULL
cites	NULL
42	NULL
articles	NULL
,	NULL
12	NULL
of	NULL
which	NULL
you	NULL
can	NULL
access	NULL
for	NULL
free	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www	NULL
.jimmunol.org/content/161/5/2201	NULL
full	NULL
#	NULL
ref-list-1	NULL
Why	NULL
The	NULL
JT	NULL
?	NULL

Submit	NULL
online	NULL
.	NULL

«	NULL
Rapid	NULL
Reviews	NULL
!	NULL

30	NULL
days*	NULL
from	NULL
submission	NULL
to	NULL
initial	NULL
decision	NULL
*	NULL
No	NULL
Triage	NULL
!	NULL

Every	NULL
submission	NULL
reviewed	NULL
by	NULL
practicing	NULL
scientists	NULL
*	NULL
Fast	NULL
Publication	NULL
!	NULL

4	NULL
weeks	NULL
from	NULL
acceptance	NULL
to	NULL
publication	NULL
*average	NULL
Subscription	NULL
_-	NULL
Information	NULL
about	NULL
subscribing	NULL
to	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
is	NULL
online	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//jimmunol.org/subscription	NULL
Permissions	NULL
_	NULL
Submit	NULL
copyright	NULL
permission	NULL
requests	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.aai.org/About/Publications/Jl/copyright.html	NULL
Email	NULL
Alerts	NULL
_	NULL
Receive	NULL
free	NULL
email-alerts	NULL
when	NULL
new	NULL
articles	NULL
cite	NULL
this	NULL
article	NULL
.	NULL

Sign	NULL
up	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//jimmunol.org/alerts	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
is	NULL
published	NULL
twice	NULL
each	NULL
month	NULL
by	NULL
The	NULL
American	NULL
Association	NULL
of	NULL
Immunologists	NULL
,	NULL
Inc.	NULL
,	NULL
1451	NULL
Rockville	NULL
Pike	NULL
,	NULL
Suite	NULL
650	NULL
,	NULL
Rockville	NULL
,	NULL
MD	NULL
20852	NULL
Copyright	NULL
©	NULL
1998	NULL
by	NULL
The	NULL
American	NULL
Association	NULL
of	NULL
Immunologists	NULL
All	NULL
rights	NULL
reserved	NULL
.	NULL

Print	NULL
ISSN	NULL
:	NULL
0022-1767	NULL
Online	NULL
ISSN	NULL
:	NULL
1550-6606	NULL
.	NULL

6107	NULL
'01	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
jountwrut	NULL
{	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
;	NULL
Protein	NULL
Kinase	NULL
C	NULL
Regulates	NULL
Fas	NULL
(	NULL
CD95/APO-1	NULL
)	NULL
Expression1	NULL
Ruoxiang	NULL
Wang	NULL
,	NULL
Liying	NULL
Zhang	NULL
,	NULL
Deling	NULL
Yin	NULL
,	NULL
R.	NULL
Allan	NULL
Mufson	NULL
``	NULL
,	NULL
and	NULL
Yufang	NULL
Shi°	NULL
Fas	NULL
(	NULL
CD95/APO-1	NULL
)	NULL
is	NULL
a	NULL
transmembrane	NULL
protein	NULL
of	NULL
the	NULL
TNF/neuron	NULL
growth	NULL
factor	NULL
receptor	NULL
family	NULL
.	NULL

Ligation	NULL
of	NULL
Fas	NULL
by	NULL
specific	NULL
Abs	NULL
or	NULL
Fas	NULL
ligand	NULL
(	NULL
FasL/CD95	NULL
ligand	NULL
)	NULL
induces	NULL
rapid	NULL
apoptotic	NULL
cell	NULL
death	NULL
in	NULL
a	NULL
variety	NULL
of	NULL
cell	NULL
types	NULL
.	NULL

Despite	NULL
progress	NULL
in	NULL
understanding	NULL
the	NULL
death	NULL
signals	NULL
transduced	NULL
from	NULL
Fas	NULL
,	NULL
very	NULL
little	NULL
is	NULL
known	NULL
with	NULL
regard	NULL
to	NULL
the	NULL
mechanisms	NULL
by	NULL
which	NULL
Fas	NULL
expression	NULL
is	NULL
regulated	NULL
.	NULL

Using	NULL
our	NULL
previously	NULL
established	NULL
murine	NULL
T	NULL
cell	NULL
hybridoma	NULL
model	NULL
A1.1	NULL
,	NULL
we	NULL
show	NULL
that	NULL
specific	NULL
protein	NULL
kinase	NULL
C	NULL
(	NULL
PKC	NULL
)	NULL
inhibitors	NULL
could	NULL
block	NULL
activation-induced	NULL
Fas	NULL
expression	NULL
and	NULL
apoptosis	NULL
.	NULL

The	NULL
activation	NULL
of	NULL
PKC	NULL
with	NULL
PMA	NULL
or	NULL
l-oleoyl-2-acetyl-sn-glycerol	NULL
could	NULL
mimic	NULL
the	NULL
TCR	NULL
signal	NULL
by	NULL
inducing	NULL
the	NULL
expression	NULL
of	NULL
Fas	NULL
but	NULL
not	NULL
FasL	NULL
.	NULL

PKC-dependent	NULL
Fas	NULL
expression	NULL
was	NULL
also	NULL
observed	NULL
in	NULL
several	NULL
murine	NULL
and	NULL
human	NULL
tumor	NULL
cell	NULL
lines	NULL
.	NULL

Since	NULL
the	NULL
inhibition	NULL
of	NULL
Ca**	NULL
redistribution	NULL
by	NULL
an	NULL
inhibitor	NULL
of	NULL
intracellular	NULL
Ca**	NULL
mobilization	NULL
,	NULL
8-	NULL
(	NULL
diethylamino	NULL
)	NULL
-octyl-3,4,5-trimethoxybenzoate	NULL
hydrochloride	NULL
,	NULL
inhibited	NULL
TCR-induced	NULL
FasL	NULL
but	NULL
not	NULL
Fas	NULL
,	NULL
the	NULL
expression	NULL
of	NULL
Fas	NULL
appears	NULL
to	NULL
be	NULL
independent	NULL
of	NULL
Ca**	NULL
mobilization	NULL
.	NULL

Significantly	NULL
,	NULL
expression	NULL
of	NULL
the	NULL
newly	NULL
identified	NULL
Fas-regulatory	NULL
gene	NULL
,	NULL
TDAGS1I	NULL
,	NULL
was	NULL
found	NULL
to	NULL
be	NULL
dependent	NULL
upon	NULL
the	NULL
activity	NULL
of	NULL
PKC	NULL
.	NULL

PKC	NULL
activation	NULL
only	NULL
induced	NULL
Fas	NULL
expression	NULL
in	NULL
cells	NULL
expressing	NULL
wild-type	NULL
TDAGS1	NULL
.	NULL

Thus	NULL
,	NULL
Fas	NULL
expression	NULL
is	NULL
likely	NULL
mediated	NULL
by	NULL
PKC	NULL
through	NULL
TDAGS1	NULL
.	NULL

The	NULL
Journal	NULL
of	NULL
Immunology	NULL
,	NULL
1998	NULL
,	NULL
161	NULL
:	NULL
2201-2207.	NULL
ctivation	NULL
of	NULL
the	NULL
TCR	NULL
leads	NULL
to	NULL
the	NULL
expression	NULL
of	NULL
a	NULL
series	NULL
A	NULL
of	NULL
genes	NULL
related	NULL
to	NULL
either	NULL
apoptosis	NULL
or	NULL
cell	NULL
proliferation	NULL
(	NULL
1	NULL
,	NULL
2	NULL
)	NULL
.	NULL

Whether	NULL
cell	NULL
proliferation	NULL
,	NULL
differentiation	NULL
,	NULL
or	NULL
apoptosis	NULL
is	NULL
favored	NULL
depends	NULL
upon	NULL
the	NULL
cellular	NULL
stage	NULL
and	NULL
the	NULL
extracellular	NULL
milieu	NULL
(	NULL
2-4	NULL
)	NULL
.	NULL

The	NULL
activation	NULL
of	NULL
immature	NULL
T	NULL
cells	NULL
during	NULL
thymic	NULL
development	NULL
induces	NULL
apoptosis	NULL
(	NULL
5-7	NULL
)	NULL
.	NULL

Although	NULL
TCR	NULL
stimulation	NULL
of	NULL
resting	NULL
peripheral	NULL
T	NULL
cells	NULL
usually	NULL
leads	NULL
to	NULL
proliferation	NULL
and	NULL
clonal	NULL
expansion	NULL
,	NULL
primary	NULL
activated	NULL
mature	NULL
T	NULL
cells	NULL
(	NULL
8-10	NULL
)	NULL
and	NULL
peripheral	NULL
mature	NULL
T	NULL
cells	NULL
from	NULL
HIV-infected	NULL
patients	NULL
(	NULL
11	NULL
)	NULL
are	NULL
also	NULL
sensitive	NULL
to	NULL
activation-induced	NULL
cell	NULL
death	NULL
(	NULL
AICD	NULL
)	NULL
.	NULL

*	NULL
Thus	NULL
,	NULL
AICD	NULL
in	NULL
T	NULL
cells	NULL
is	NULL
a	NULL
fundamental	NULL
mechanism	NULL
for	NULL
maintaining	NULL
immune	NULL
tolerance	NULL
and	NULL
cellular	NULL
homeostasis	NULL
during	NULL
T	NULL
cell	NULL
development	NULL
,	NULL
immune	NULL
responses	NULL
,	NULL
and	NULL
disease	NULL
(	NULL
12	NULL
,	NULL
13	NULL
)	NULL
.	NULL

Similar	NULL
to	NULL
immature	NULL
thymic	NULL
lymphocytes	NULL
and	NULL
activated	NULL
mature	NULL
T	NULL
cells	NULL
,	NULL
T	NULL
cell	NULL
hybridomas	NULL
also	NULL
undergo	NULL
AICD	NULL
following	NULL
TCR	NULL
cross-linking	NULL
(	NULL
14-17	NULL
)	NULL
.	NULL

Recent	NULL
studies	NULL
have	NULL
demonstrated	NULL
that	NULL
AICD	NULL
in	NULL
T	NULL
cell	NULL
hybridomas	NULL
is	NULL
dependent	NULL
upon	NULL
the	NULL
induction	NULL
of	NULL
Fas	NULL
(	NULL
CD95	NULL
)	NULL
and	NULL
Fas	NULL
ligand	NULL
(	NULL
FasL/CD95	NULL
ligand	NULL
)	NULL
(	NULL
18-20	NULL
)	NULL
.	NULL

Importantly	NULL
,	NULL
competitive	NULL
inhibition	NULL
of	NULL
the	NULL
interaction	NULL
between	NULL
Fas	NULL
and	NULL
FasL	NULL
with	NULL
soluble	NULL
Fas	NULL
proteins	NULL
effectively	NULL
inhibited	NULL
AICD	NULL
(	NULL
19	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
Department	NULL
of	NULL
Immunology	NULL
,	NULL
Jerome	NULL
H.	NULL
Holland	NULL
Laboratory	NULL
,	NULL
American	NULL
Red	NULL
Cross	NULL
,	NULL
Rockville	NULL
,	NULL
MD	NULL
20855	NULL
Received	NULL
for	NULL
publication	NULL
December	NULL
5	NULL
,	NULL
1998	NULL
.	NULL

Accepted	NULL
for	NULL
publication	NULL
April	NULL
30	NULL
,	NULL
1998	NULL
.	NULL

The	NULL
costs	NULL
of	NULL
publication	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
the	NULL
payment	NULL
of	NULL
page	NULL
charges	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
advertisement	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

Section	NULL
1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

*	NULL
This	NULL
project	NULL
is	NULL
supported	NULL
by	NULL
Research	NULL
Grant	NULL
No	NULL
.	NULL

4426	NULL
from	NULL
the	NULL
Council	NULL
for	NULL
Tobacco	NULL
Research-USA	NULL
Inc.	NULL
,	NULL
a	NULL
research	NULL
fund	NULL
from	NULL
The	NULL
Jerome	NULL
H.	NULL
Holland	NULL
Laboratory	NULL
of	NULL
the	NULL
American	NULL
Red	NULL
Cross	NULL
,	NULL
and	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
Grants	NULL
€CA53609-6	NULL
and	NULL
Al43384-01	NULL
.	NULL

This	NULL
is	NULL
publication	NULL
number	NULL
34	NULL
of	NULL
the	NULL
Department	NULL
of	NULL
Immunology	NULL
,	NULL
Holland	NULL
Laboratory	NULL
.	NULL

2	NULL
Current	NULL
address	NULL
:	NULL
Cancer	NULL
Immunology	NULL
Branch	NULL
,	NULL
National	NULL
Cancer	NULL
Institute	NULL
,	NULL
Bethesda	NULL
,	NULL
MD	NULL
20892-7381	NULL
.	NULL

3	NULL
Address	NULL
correspondence	NULL
and	NULL
reprint	NULL
requests	NULL
to	NULL
Dr.	NULL
Yufang	NULL
Shi	NULL
,	NULL
Department	NULL
of	NULL
Immunology	NULL
,	NULL
Jerome	NULL
H.	NULL
Holland	NULL
Laboratory	NULL
,	NULL
American	NULL
Red	NULL
Cross	NULL
,	NULL
15601	NULL
Crabbs	NULL
Branch	NULL
Way	NULL
,	NULL
Rockville	NULL
,	NULL
MD	NULL
20855	NULL
.	NULL

E-mail	NULL
address	NULL
:	NULL
shiy	NULL
@	NULL
usa.redcross.org	NULL
*	NULL
Abbreviations	NULL
used	NULL
in	NULL
this	NULL
paper	NULL
:	NULL
AICD	NULL
,	NULL
activation-induced	NULL
cell	NULL
death	NULL
;	NULL
FasL	NULL
,	NULL
Fas	NULL
ligand	NULL
;	NULL
PKC	NULL
,	NULL
protein	NULL
kinase	NULL
C	NULL
;	NULL
CsA	NULL
,	NULL
cyclosporin	NULL
A	NULL
;	NULL
OAG	NULL
,	NULL
1-oleoyl-2-acetyl-sn-glyc-erol	NULL
;	NULL
TMB-8	NULL
,	NULL
8-	NULL
(	NULL
diethylamino	NULL
)	NULL
-octy1-3,4,5-trimethoxybenzoate	NULL
hydrochloride	NULL
;	NULL
MTT	NULL
,	NULL
3-	NULL
(	NULL
4,5-dimethylthiazol-2-y1	NULL
)	NULL
-2,5-diphenyl	NULL
tetrazolium	NULL
bromide	NULL
.	NULL

Copyright	NULL
©	NULL
1998	NULL
by	NULL
The	NULL
American	NULL
Association	NULL
of	NULL
Immunologists	NULL
Fas	NULL
and	NULL
FasL	NULL
play	NULL
a	NULL
fundamental	NULL
role	NULL
in	NULL
AICD	NULL
in	NULL
T	NULL
cells	NULL
and	NULL
T	NULL
cell	NULL
hybridomas	NULL
.	NULL

The	NULL
activation	NULL
of	NULL
Fas	NULL
through	NULL
its	NULL
interaction	NULL
with	NULL
FasL	NULL
or	NULL
with	NULL
specific	NULL
anti-Fas	NULL
Abs	NULL
triggers	NULL
the	NULL
activation	NULL
of	NULL
a	NULL
cascade	NULL
of	NULL
pro-teases	NULL
;	NULL
these	NULL
proteases	NULL
,	NULL
in	NULL
turn	NULL
,	NULL
execute	NULL
the	NULL
apoptotic	NULL
process	NULL
(	NULL
21	NULL
)	NULL
.	NULL

Interestingly	NULL
,	NULL
the	NULL
apoptosis	NULL
signals	NULL
after	NULL
Fas	NULL
ligation	NULL
are	NULL
independent	NULL
of	NULL
macromolecular	NULL
synthesis	NULL
(	NULL
22	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
the	NULL
expression	NULL
of	NULL
Fas	NULL
is	NULL
the	NULL
key	NULL
checkpoint	NULL
for	NULL
cells	NULL
to	NULL
commit	NULL
to	NULL
AICD	NULL
.	NULL

In	NULL
many	NULL
cellular	NULL
systems	NULL
,	NULL
the	NULL
expression	NULL
of	NULL
Fas	NULL
is	NULL
strictly	NULL
controlled	NULL
(	NULL
23	NULL
)	NULL
.	NULL

An	NULL
overexpression	NULL
of	NULL
Fas	NULL
rendered	NULL
cells	NULL
highly	NULL
sensitive	NULL
to	NULL
FasL-mediated	NULL
killing	NULL
(	NULL
24	NULL
,	NULL
25	NULL
)	NULL
.	NULL

However	NULL
,	NULL
the	NULL
regulation	NULL
of	NULL
Fas	NULL
expression	NULL
is	NULL
poorly	NULL
understood	NULL
.	NULL

Thus	NULL
,	NULL
elucidation	NULL
of	NULL
the	NULL
regulatory	NULL
mechanisms	NULL
for	NULL
Fas	NULL
expression	NULL
could	NULL
provide	NULL
important	NULL
information	NULL
for	NULL
a	NULL
better	NULL
understanding	NULL
of	NULL
the	NULL
molecular	NULL
mechanisms	NULL
of	NULL
apoptosis	NULL
.	NULL

Ligation	NULL
of	NULL
the	NULL
TCR	NULL
by	NULL
specific	NULL
Ag	NULL
peptide	NULL
presented	NULL
by	NULL
the	NULL
MHC	NULL
on	NULL
APCs	NULL
initiates	NULL
a	NULL
biochemical	NULL
cascade	NULL
that	NULL
involves	NULL
the	NULL
activation	NULL
of	NULL
protein	NULL
tyrosine	NULL
kinases	NULL
and	NULL
protein	NULL
tyrosine	NULL
phos-phatases	NULL
(	NULL
1	NULL
,	NULL
2	NULL
)	NULL
.	NULL

These	NULL
enzymes	NULL
change	NULL
the	NULL
phosphorylation	NULL
status	NULL
of	NULL
a	NULL
number	NULL
of	NULL
intracellular	NULL
substrates	NULL
participating	NULL
in	NULL
the	NULL
signal	NULL
transduction	NULL
cascade	NULL
,	NULL
which	NULL
leads	NULL
to	NULL
the	NULL
activation	NULL
of	NULL
protein	NULL
kinase	NULL
C	NULL
(	NULL
PKC	NULL
)	NULL
and	NULL
to	NULL
Ca**	NULL
mobilization	NULL
(	NULL
13	NULL
)	NULL
.	NULL

Since	NULL
PKC	NULL
activation	NULL
and	NULL
Ca**	NULL
redistribution	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
critical	NULL
in	NULL
TCR-mediated	NULL
activation	NULL
signals	NULL
,	NULL
we	NULL
examined	NULL
the	NULL
role	NULL
of	NULL
these	NULL
signals	NULL
in	NULL
Fas	NULL
and	NULL
FasL	NULL
expression	NULL
during	NULL
AICD	NULL
.	NULL

An	NULL
increase	NULL
in	NULL
cytosolic	NULL
Ca**	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
fundamental	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
FasL	NULL
expression	NULL
,	NULL
since	NULL
the	NULL
activation-induced	NULL
expression	NULL
of	NULL
FasL	NULL
could	NULL
be	NULL
completely	NULL
inhibited	NULL
by	NULL
cyclosporin	NULL
A	NULL
(	NULL
CsA	NULL
)	NULL
and	NULL
FK506	NULL
(	NULL
26	NULL
)	NULL
.	NULL

Nevertheless	NULL
,	NULL
the	NULL
role	NULL
of	NULL
PKC	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
Fas	NULL
and	NULL
FasL	NULL
expression	NULL
is	NULL
not	NULL
clear	NULL
.	NULL

We	NULL
report	NULL
that	NULL
the	NULL
activation	NULL
of	NULL
PKC	NULL
without	NULL
intracellular	NULL
Ca**	NULL
mobilization	NULL
is	NULL
sufficient	NULL
to	NULL
induce	NULL
Fas	NULL
expression	NULL
.	NULL

Interestingly	NULL
,	NULL
FasL	NULL
expression	NULL
requires	NULL
both	NULL
PKC	NULL
activation	NULL
and	NULL
intracellular	NULL
Ca	NULL
``	NULL
*	NULL
redistribution	NULL
.	NULL

Materials	NULL
and	NULL
Methods	NULL
Cells	NULL
,	NULL
reagents	NULL
,	NULL
and	NULL
Abs	NULL
Murine	NULL
T	NULL
cell	NULL
hybridoma	NULL
(	NULL
A1.1	NULL
)	NULL
cells	NULL
(	NULL
27	NULL
)	NULL
,	NULL
B	NULL
cell	NULL
lymphoma	NULL
CH31	NULL
(	NULL
a	NULL
gift	NULL
of	NULL
Dr.	NULL
David	NULL
Scott	NULL
,	NULL
Holland	NULL
Laboratory	NULL
of	NULL
the	NULL
American	NULL
Red	NULL
Cross	NULL
)	NULL
,	NULL
T	NULL
cell	NULL
hybridoma	NULL
KCIT	NULL
and	NULL
its	NULL
mutants	NULL
(	NULL
kindly	NULL
provided	NULL
by	NULL
Dr.	NULL
Yongwon	NULL
Choi	NULL
,	NULL
Rockefeller	NULL
University	NULL
,	NULL
New	NULL
York	NULL
,	NULL
NY	NULL
)	NULL
,	NULL
and	NULL
human	NULL
Jurkat	NULL
cells	NULL
were	NULL
0022-1767/98/	NULL
$	NULL
02.00	NULL
6107	NULL
'01	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
jountwrut	NULL
{	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
;	NULL
2202	NULL
maintained	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
(	NULL
Life	NULL
Technologies	NULL
,	NULL
Gaithersburg	NULL
,	NULL
MD	NULL
)	NULL
that	NULL
was	NULL
supplemented	NULL
with	NULL
2	NULL
mM	NULL
L-glutamine	NULL
,	NULL
50	NULL
mM	NULL
2-ME	NULL
,	NULL
10	NULL
%	NULL
heat-inactivated	NULL
FBS	NULL
(	NULL
Sigma	NULL
,	NULL
St.	NULL
Louis	NULL
,	NULL
MO	NULL
)	NULL
,	NULL
and	NULL
10	NULL
mM	NULL
gentamicin	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
IL-2	NULL
was	NULL
added	NULL
to	NULL
the	NULL
CTLL2	NULL
culture	NULL
at	NULL
a	NULL
concentration	NULL
of	NULL
100	NULL
U/ml	NULL
.	NULL

Cultures	NULL
were	NULL
incubated	NULL
at	NULL
37°C	NULL
in	NULL
humidified	NULL
atmosphere	NULL
with	NULL
5	NULL
%	NULL
CO	NULL
,	NULL
.	NULL

Ab	NULL
to	NULL
CD3	NULL
was	NULL
produced	NULL
by	NULL
a	NULL
hamster	NULL
B	NULL
cell	NULL
hybridoma	NULL
,	NULL
145-2C11e	NULL
(	NULL
obtained	NULL
from	NULL
Dr.	NULL
Jeffery	NULL
Bluestone	NULL
,	NULL
University	NULL
of	NULL
Chicago	NULL
,	NULL
Chicago	NULL
,	NULL
IL	NULL
)	NULL
.	NULL

PMA	NULL
,	NULL
1-oleoyl-2-acetyl-sn-glycerol	NULL
(	NULL
OAG	NULL
)	NULL
,	NULL
N-	NULL
(	NULL
2-guanidinoethy1	NULL
)	NULL
-5-iso-quinolinesulfonamide	NULL
(	NULL
HA	NULL
1004	NULL
)	NULL
,	NULL
1-	NULL
(	NULL
5-isoquinolinesulfonyl	NULL
)	NULL
-2-meth-ylpiperazine	NULL
(	NULL
H7	NULL
)	NULL
,	NULL
666976	NULL
,	NULL
bisindolylmaleimide	NULL
I	NULL
,	NULL
calphostin	NULL
C	NULL
,	NULL
and	NULL
ionomycin	NULL
were	NULL
purchased	NULL
from	NULL
Calbiochem	NULL
(	NULL
San	NULL
Diego	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

An	NULL
inhibitor	NULL
of	NULL
intracellular	NULL
Ca	NULL
``	NULL
*	NULL
mobilization	NULL
,	NULL
8-	NULL
(	NULL
diethylamino	NULL
)	NULL
-octyl-3,4,5-trimethoxybenzoate	NULL
hydrochloride	NULL
(	NULL
TMB-8	NULL
)	NULL
,	NULL
was	NULL
obtained	NULL
from	NULL
Sigma	NULL
.	NULL

A	NULL
PKC	NULL
iso-form-typing	NULL
kit	NULL
was	NULL
obtained	NULL
from	NULL
Transduction	NULL
Laboratory	NULL
(	NULL
Lexington	NULL
,	NULL
KY	NULL
)	NULL
.	NULL

The	NULL
other	NULL
chemicals	NULL
used	NULL
were	NULL
of	NULL
the	NULL
purest	NULL
grade	NULL
available	NULL
from	NULL
Sigma	NULL
.	NULL

DNA	NULL
fragmentation	NULL
assay	NULL
A	NULL
DNA	NULL
fragmentation	NULL
assay	NULL
was	NULL
conducted	NULL
essentially	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
15	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
5	NULL
X	NULL
10°	NULL
cells	NULL
were	NULL
suspended	NULL
in	NULL
30	NULL
pul	NULL
of	NULL
Ca**	NULL
-free	NULL
PBS	NULL
and	NULL
lysed	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
30	NULL
gl	NULL
of	NULL
lysis	NULL
buffer	NULL
(	NULL
80	NULL
mM	NULL
EDTA	NULL
,	NULL
200	NULL
mM	NULL
Tris	NULL
(	NULL
pH	NULL
8.0	NULL
)	NULL
,	NULL
1.6	NULL
%	NULL
sodium	NULL
lauryl	NULL
sarcosinate	NULL
,	NULL
and	NULL
1	NULL
mg/ml	NULL
proteinase	NULL
K	NULL
)	NULL
.	NULL

Cell	NULL
lysates	NULL
were	NULL
incubated	NULL
at	NULL
50°C	NULL
for	NULL
4	NULL
h	NULL
followed	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
RNase	NULL
A	NULL
to	NULL
a	NULL
final	NULL
concentration	NULL
of	NULL
0.2	NULL
mg/ml	NULL
.	NULL

After	NULL
incubation	NULL
at	NULL
37°C	NULL
for	NULL
another	NULL
30	NULL
min	NULL
,	NULL
the	NULL
resulting	NULL
DNA	NULL
samples	NULL
were	NULL
fractionated	NULL
by	NULL
agarose	NULL
gel	NULL
electrophoresis	NULL
and	NULL
visualized	NULL
under	NULL
UV	NULL
light	NULL
after	NULL
staining	NULL
with	NULL
ethidium	NULL
bromide	NULL
.	NULL

DNA	NULL
content	NULL
analysis	NULL
Genomic	NULL
DNA	NULL
integrity	NULL
was	NULL
also	NULL
analyzed	NULL
by	NULL
determining	NULL
the	NULL
DNA	NULL
content	NULL
in	NULL
the	NULL
nuclei	NULL
by	NULL
flow	NULL
cytometry	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
28	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
fixed	NULL
with	NULL
70	NULL
%	NULL
ethanol	NULL
for	NULL
30	NULL
min	NULL
at	NULL
4°C	NULL
,	NULL
followed	NULL
by	NULL
two	NULL
washes	NULL
with	NULL
PBS	NULL
.	NULL

The	NULL
fixed	NULL
cells	NULL
were	NULL
then	NULL
incubated	NULL
in	NULL
PBS	NULL
containing	NULL
propidium	NULL
iodide	NULL
(	NULL
Sigma	NULL
)	NULL
at	NULL
50	NULL
pg/ml	NULL
and	NULL
RNase	NULL
(	NULL
Boehringer	NULL
Mannheim	NULL
,	NULL
Indianapolis	NULL
,	NULL
IN	NULL
)	NULL
at	NULL
0.1	NULL
mg/ml	NULL
at	NULL
room	NULL
temperature	NULL
for	NULL
30	NULL
min	NULL
.	NULL

DNA	NULL
content	NULL
was	NULL
determined	NULL
by	NULL
flow	NULL
cytometry	NULL
on	NULL
a	NULL
FACScan	NULL
(	NULL
Becton	NULL
Dick-inson	NULL
,	NULL
San	NULL
Jose	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

The	NULL
FL2	NULL
intensity	NULL
was	NULL
plotted	NULL
as	NULL
histograms	NULL
on	NULL
a	NULL
linear	NULL
scale	NULL
.	NULL

IL-2	NULL
ELISA	NULL
The	NULL
TCR	NULL
activation-induced	NULL
production	NULL
of	NULL
IL-2	NULL
in	NULL
culture	NULL
supernatants	NULL
was	NULL
measured	NULL
using	NULL
a	NULL
Cytoscreen	NULL
Immunoassay	NULL
Kit	NULL
obtained	NULL
from	NULL
BioSource	NULL
(	NULL
Camarillo	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

The	NULL
murine	NULL
rIL-2	NULL
included	NULL
in	NULL
the	NULL
kit	NULL
was	NULL
diluted	NULL
to	NULL
generate	NULL
a	NULL
standard	NULL
curve	NULL
.	NULL

An	NULL
ELISA	NULL
was	NULL
performed	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
instructions	NULL
.	NULL

Briefly	NULL
,	NULL
culture	NULL
supernatants	NULL
were	NULL
diluted	NULL
in	NULL
the	NULL
standard	NULL
diluent	NULL
buffer	NULL
included	NULL
in	NULL
the	NULL
kit	NULL
.	NULL

Standard	NULL
dilutions	NULL
and	NULL
samples	NULL
were	NULL
incubated	NULL
on	NULL
the	NULL
first	NULL
anti-IL-2	NULL
Ab-coated	NULL
microtiter	NULL
plates	NULL
for	NULL
1.5	NULL
h	NULL
at	NULL
37°C	NULL
.	NULL

After	NULL
washing	NULL
with	NULL
the	NULL
washing	NULL
buffer	NULL
(	NULL
PBS	NULL
plus	NULL
0.2	NULL
%	NULL
Tween	NULL
20	NULL
)	NULL
,	NULL
the	NULL
bound	NULL
IL-2	NULL
was	NULL
detected	NULL
with	NULL
a	NULL
biotinylated	NULL
second	NULL
anti-IL-2	NULL
Ab	NULL
and	NULL
streptavidin-peroxidase	NULL
.	NULL

The	NULL
amount	NULL
of	NULL
IL-2	NULL
was	NULL
determined	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
tetramethyl	NULL
benzidine	NULL
.	NULL

Analysis	NULL
of	NULL
functional	NULL
Fas	NULL
expression	NULL
Activation-induced	NULL
Fas	NULL
expression	NULL
on	NULL
murine	NULL
T	NULL
cell	NULL
hybridomas	NULL
was	NULL
assessed	NULL
by	NULL
determining	NULL
the	NULL
sensitivity	NULL
to	NULL
killing	NULL
by	NULL
anti-Fas	NULL
Ab	NULL
(	NULL
JO2	NULL
)	NULL
or	NULL
by	NULL
L	NULL
cells	NULL
expressing	NULL
sense	NULL
FasL	NULL
but	NULL
not	NULL
antisense	NULL
FasL	NULL
(	NULL
kindly	NULL
provided	NULL
by	NULL
Dr.	NULL
T.	NULL
A.	NULL
Ferguson	NULL
,	NULL
Washington	NULL
University	NULL
School	NULL
of	NULL
Medicine	NULL
,	NULL
St.	NULL
Louis	NULL
,	NULL
MO	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
cells	NULL
were	NULL
incubated	NULL
with	NULL
JO2	NULL
or	NULL
L	NULL
cells	NULL
after	NULL
appropriate	NULL
treatments	NULL
.	NULL

Apoptosis	NULL
was	NULL
determined	NULL
by	NULL
flow	NULL
cytometric	NULL
DNA	NULL
content	NULL
analysis	NULL
as	NULL
described	NULL
above	NULL
.	NULL

3-	NULL
(	NULL
4,5-dimethylthiazol-2-yl	NULL
)	NULL
-2,5-diphenyl	NULL
tetrazolium	NULL
bromide	NULL
(	NULL
MTT	NULL
)	NULL
assay	NULL
Cell	NULL
viability	NULL
was	NULL
measured	NULL
by	NULL
MTT	NULL
conversion	NULL
(	NULL
29	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
cells	NULL
were	NULL
incubated	NULL
in	NULL
complete	NULL
RPMI	NULL
1640	NULL
medium	NULL
in	NULL
96-well	NULL
plates	NULL
.	NULL

After	NULL
treatments	NULL
as	NULL
indicated	NULL
,	NULL
10	NULL
gl	NULL
of	NULL
MTT	NULL
(	NULL
5	NULL
mg/ml	NULL
in	NULL
H	NULL
;	NULL
O	NULL
)	NULL
was	NULL
introduced	NULL
,	NULL
and	NULL
cells	NULL
were	NULL
incubated	NULL
at	NULL
37°C	NULL
for	NULL
4	NULL
h	NULL
followed	NULL
by	NULL
addition	NULL
of	NULL
100	NULL
pl	NULL
of	NULL
acid-isopropanol	NULL
(	NULL
0.04	NULL
N	NULL
HCI	NULL
)	NULL
.	NULL

After	NULL
the	NULL
reduced	NULL
MTT	NULL
crystals	NULL
were	NULL
dis-solved	NULL
,	NULL
the	NULL
plate	NULL
was	NULL
immediately	NULL
scanned	NULL
by	NULL
an	NULL
ELISA	NULL
reader	NULL
with	NULL
a	NULL
595-nM	NULL
filter	NULL
.	NULL

Northern	NULL
blotting	NULL
Total	NULL
RNA	NULL
was	NULL
isolated	NULL
with	NULL
affinity	NULL
columns	NULL
(	NULL
Qiagen	NULL
,	NULL
Chatsworth	NULL
,	NULL
CA	NULL
)	NULL
according	NULL
to	NULL
the	NULL
protocol	NULL
recommended	NULL
by	NULL
the	NULL
manufacturer	NULL
.	NULL

RNA	NULL
samples	NULL
were	NULL
fractionated	NULL
on	NULL
1	NULL
%	NULL
agarose/2.2	NULL
M	NULL
formaldehyde	NULL
denaturing	NULL
gel	NULL
PKC	NULL
MEDIATES	NULL
Fas	NULL
EXPRESSION	NULL
and	NULL
transferred	NULL
onto	NULL
a	NULL
Nytran	NULL
membrane	NULL
(	NULL
Schleicher	NULL
and	NULL
Schuell	NULL
,	NULL
Keene	NULL
,	NULL
NH	NULL
)	NULL
.	NULL

The	NULL
DNA	NULL
probes	NULL
(	NULL
mouse	NULL
Fas	NULL
and	NULL
FasL	NULL
were	NULL
provided	NULL
by	NULL
Dr.	NULL
Shigekazu	NULL
Nagata	NULL
,	NULL
Osaka	NULL
Bioscience	NULL
Institute	NULL
,	NULL
Osaka	NULL
,	NULL
Japan	NULL
;	NULL
TDAGS1	NULL
was	NULL
obtained	NULL
from	NULL
Dr.	NULL
Yongwon	NULL
Choi	NULL
)	NULL
were	NULL
labeled	NULL
by	NULL
random	NULL
priming	NULL
(	NULL
Boehringer	NULL
Mannheim	NULL
)	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
instructions	NULL
.	NULL

Pre-hybridization	NULL
and	NULL
hybridization	NULL
were	NULL
conducted	NULL
at	NULL
42°C	NULL
in	NULL
a	NULL
solution	NULL
containing	NULL
5X	NULL
SSC	NULL
(	NULL
10	NULL
%	NULL
SSC	NULL
is	NULL
1.5	NULL
M	NULL
NaCl	NULL
,	NULL
and	NULL
0.15	NULL
M	NULL
sodium	NULL
citrate	NULL
)	NULL
,	NULL
2.5	NULL
mM	NULL
EDTA	NULL
,	NULL
0.1	NULL
%	NULL
SDS	NULL
,	NULL
5X	NULL
Denhardt	NULL
's	NULL
solution	NULL
,	NULL
2	NULL
mM	NULL
sodium	NULL
pyrophos-phate	NULL
,	NULL
50	NULL
mM	NULL
sodium	NULL
phosphate	NULL
,	NULL
and	NULL
50	NULL
%	NULL
formamide	NULL
.	NULL

After	NULL
washing	NULL
with	NULL
0.2X	NULL
SSC	NULL
and	NULL
0.1	NULL
%	NULL
SDS	NULL
at	NULL
56°C	NULL
for	NULL
1	NULL
h	NULL
,	NULL
hybridization	NULL
signals	NULL
were	NULL
detected	NULL
by	NULL
autoradiography	NULL
.	NULL

Results	NULL
Both	NULL
PKC	NULL
activation	NULL
and	NULL
Ca	NULL
``	NULL
*	NULL
influx	NULL
are	NULL
required	NULL
for	NULL
AICD	NULL
Murine	NULL
T	NULL
cell	NULL
hybridoma	NULL
A1.1	NULL
cells	NULL
commit	NULL
to	NULL
AICD	NULL
in	NULL
a	NULL
Fas-	NULL
and	NULL
FasL-dependent	NULL
manner	NULL
(	NULL
15	NULL
,	NULL
19	NULL
)	NULL
.	NULL

AICD	NULL
occurs	NULL
in	NULL
a	NULL
period	NULL
of	NULL
8	NULL
h	NULL
,	NULL
with	NULL
a	NULL
sequential	NULL
induction	NULL
of	NULL
Fas	NULL
at	NULL
2	NULL
h	NULL
and	NULL
FasL	NULL
at	NULL
4	NULL
h	NULL
following	NULL
TCR	NULL
cross-linking	NULL
(	NULL
19	NULL
)	NULL
.	NULL

Ligation	NULL
of	NULL
the	NULL
TCR	NULL
initiates	NULL
a	NULL
signal	NULL
transduction	NULL
cascade	NULL
in	NULL
which	NULL
Ca**	NULL
influx	NULL
and	NULL
the	NULL
activation	NULL
of	NULL
PKC	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
the	NULL
critical	NULL
points	NULL
in	NULL
activation-induced	NULL
cytokine	NULL
production	NULL
and	NULL
proliferation	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
combination	NULL
of	NULL
PMA	NULL
and	NULL
Ca**	NULL
ionophore	NULL
mimics	NULL
the	NULL
signals	NULL
from	NULL
the	NULL
TCR	NULL
(	NULL
13	NULL
)	NULL
.	NULL

Here	NULL
,	NULL
we	NULL
examined	NULL
the	NULL
role	NULL
of	NULL
PKC	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
Fas	NULL
and	NULL
FasL	NULL
expression	NULL
during	NULL
AICD	NULL
.	NULL

We	NULL
initially	NULL
tested	NULL
the	NULL
requirement	NULL
of	NULL
PKC	NULL
activation	NULL
and	NULL
Ca**	NULL
influx	NULL
for	NULL
AICD	NULL
in	NULL
T	NULL
cell	NULL
hybridomas	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Figure	NULL
1	NULL
,	NULL
treating	NULL
A1.1	NULL
cells	NULL
with	NULL
the	NULL
Ca**	NULL
ionophere	NULL
,	NULL
ionomycin	NULL
,	NULL
plus	NULL
either	NULL
PMA	NULL
or	NULL
OAG	NULL
readily	NULL
induced	NULL
apoptosis	NULL
as	NULL
detected	NULL
by	NULL
genomic	NULL
DNA	NULL
fragmentation	NULL
(	NULL
Fig	NULL
.	NULL

14	NULL
)	NULL
and	NULL
MTT	NULL
viability	NULL
assay	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
)	NULL
.	NULL

When	NULL
applied	NULL
individually	NULL
,	NULL
neither	NULL
ionomycin	NULL
,	NULL
PMA	NULL
,	NULL
nor	NULL
OAG	NULL
was	NULL
sufficient	NULL
to	NULL
induce	NULL
apoptosis	NULL
.	NULL

Similar	NULL
to	NULL
the	NULL
activation	NULL
of	NULL
primary	NULL
T	NULL
cells	NULL
(	NULL
30	NULL
)	NULL
,	NULL
both	NULL
PKC	NULL
activation	NULL
and	NULL
Ca**	NULL
influx	NULL
are	NULL
required	NULL
for	NULL
AICD	NULL
in	NULL
the	NULL
A1l.1	NULL
hybridoma	NULL
.	NULL

To	NULL
further	NULL
investigate	NULL
the	NULL
role	NULL
of	NULL
PKC	NULL
in	NULL
the	NULL
pathway	NULL
leading	NULL
to	NULL
AICD	NULL
,	NULL
we	NULL
examined	NULL
the	NULL
effect	NULL
of	NULL
several	NULL
relatively	NULL
specific	NULL
PKC	NULL
inhibitors	NULL
(	NULL
31	NULL
)	NULL
.	NULL

We	NULL
found	NULL
that	NULL
these	NULL
inhibitors	NULL
could	NULL
effectively	NULL
block	NULL
TCR	NULL
ligation-induced	NULL
AICD	NULL
in	NULL
A1.1	NULL
hybridomas	NULL
as	NULL
demonstrated	NULL
by	NULL
DNA	NULL
content	NULL
analysis	NULL
(	NULL
Fig	NULL
.	NULL

1C	NULL
)	NULL
and	NULL
genomic	NULL
DNA	NULL
oligonucleosomal	NULL
fragmentation	NULL
(	NULL
Fig	NULL
.	NULL

11	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
we	NULL
have	NULL
performed	NULL
PKC	NULL
isoform	NULL
typing	NULL
and	NULL
found	NULL
that	NULL
a	NULL
,	NULL
y	NULL
,	NULL
8	NULL
,	NULL
e	NULL
,	NULL
1	NULL
,	NULL
and	NULL
u	NULL
were	NULL
present	NULL
in	NULL
A1l.1	NULL
cells	NULL
,	NULL
while	NULL
isoforms	NULL
B	NULL
,	NULL
&	NULL
,	NULL
and	NULL
0	NULL
,	NULL
were	NULL
not	NULL
found	NULL
(	NULL
Fig	NULL
.	NULL

1£	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
several	NULL
PKC	NULL
isoforms	NULL
are	NULL
present	NULL
in	NULL
T	NULL
cell	NULL
hybridoma	NULL
A1l.l	NULL
cells	NULL
and	NULL
are	NULL
required	NULL
for	NULL
activation-induced	NULL
apoptosis	NULL
.	NULL

Activation	NULL
of	NULL
PKC	NULL
alone	NULL
sensitizes	NULL
T	NULL
cell	NULL
hybridomas	NULL
to	NULL
anti-Fas-induced	NULL
apoptosis	NULL
The	NULL
activation-induced	NULL
expression	NULL
of	NULL
Fas	NULL
and	NULL
FasL	NULL
is	NULL
absolutely	NULL
required	NULL
for	NULL
AICD	NULL
in	NULL
T	NULL
cell	NULL
hybridomas	NULL
,	NULL
since	NULL
soluble	NULL
Fas	NULL
protein	NULL
could	NULL
completely	NULL
block	NULL
AICD	NULL
(	NULL
19	NULL
)	NULL
.	NULL

Unactivated	NULL
A1.1	NULL
cells	NULL
express	NULL
a	NULL
low	NULL
level	NULL
of	NULL
Fas	NULL
,	NULL
which	NULL
are	NULL
insensitive	NULL
to	NULL
anti-Fas	NULL
Ab-	NULL
or	NULL
FasL-expressing	NULL
fibroblast-induced	NULL
apoptosis	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

Interestingly	NULL
,	NULL
although	NULL
the	NULL
application	NULL
of	NULL
PMA	NULL
or	NULL
OAG	NULL
alone	NULL
could	NULL
not	NULL
induce	NULL
apoptosis	NULL
in	NULL
A1.1	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
,	NULL
these	NULL
treatments	NULL
primed	NULL
A1l.1	NULL
to	NULL
undergo	NULL
increased	NULL
Fas	NULL
ligation-induced	NULL
apoptosis	NULL
as	NULL
detected	NULL
by	NULL
DNA	NULL
content	NULL
analysis	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

Specifically	NULL
,	NULL
Al.l1	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
PMA	NULL
(	NULL
Fig	NULL
.	NULL

24	NULL
)	NULL
or	NULL
OAG	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
for	NULL
2	NULL
h	NULL
and	NULL
then	NULL
incubated	NULL
with	NULL
L	NULL
cells	NULL
that	NULL
had	NULL
been	NULL
transfected	NULL
with	NULL
either	NULL
sense	NULL
FasL	NULL
or	NULL
antisense	NULL
FasL	NULL
(	NULL
Fig	NULL
.	NULL

24	NULL
)	NULL
or	NULL
with	NULL
or	NULL
without	NULL
anti-Fas	NULL
(	NULL
JO2	NULL
,	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
for	NULL
12	NULL
h.	NULL
PKC	NULL
activation	NULL
with	NULL
PMA	NULL
or	NULL
OAG	NULL
sensitized	NULL
Al.1	NULL
cells	NULL
to	NULL
Fas	NULL
ligation-induced	NULL
apoptosis	NULL
as	NULL
assessed	NULL
by	NULL
DNA	NULL
content	NULL
analysis	NULL
.	NULL

There	NULL
are	NULL
two	NULL
possible	NULL
explanations	NULL
to	NULL
account	NULL
for	NULL
this	NULL
result	NULL
,	NULL
i.e	NULL
.	NULL

,	NULL
PKC	NULL
activation	NULL
either	NULL
increases	NULL
Fas	NULL
expression	NULL
or	NULL
sensitizes	NULL
the	NULL
T	NULL
cell	NULL
hybridoma	NULL
cells	NULL
to	NULL
Fas-mediated	NULL
death	NULL
signals	NULL
.	NULL

6107	NULL
'01	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
jountwrut	NULL
{	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
;	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
B	NULL
Control	NULL
Anti-CD3	NULL
Ionomycin	NULL
PMA	NULL
PMA	NULL
+	NULL
Ionomycin	NULL
OaG	NULL
OAG	NULL
+	NULL
Ionomycin	NULL
0	NULL
0.5	NULL
1.0	NULL
1.5	NULL
Relative	NULL
Cell	NULL
Viability	NULL
(	NULL
MTT	NULL
,	NULL
O.D	NULL
.	NULL

595	NULL
,	NULL
Mean	NULL
£	NULL
SE	NULL
)	NULL
C	NULL
Control	NULL
2203	NULL
Anti-CD3	NULL
Control	NULL
Control	NULL
al	NULL
po	NULL
©	NULL
o	NULL
:	NULL
F	NULL
[	NULL
kb	NULL
Uk	NULL
lk	NULL
k	NULL
9	NULL
a	NULL
>	NULL
g	NULL
O	NULL
Anti-CD3	NULL
+	NULL
HA	NULL
Anti-CD3	NULL
+	NULL
Bis	NULL
Anti-CD3	NULL
+	NULL
H7	NULL
Anti-CD3	NULL
Control	NULL
<	NULL
a	NULL
Ez	NULL
#	NULL
FIGURE	NULL
1	NULL
.	NULL

-	NULL
Activation-induced	NULL
apoptosis	NULL
requires	NULL
both	NULL
PKC	NULL
activation	NULL
and	NULL
Ca	NULL
``	NULL
*	NULL
.	NULL

A1.1	NULL
cells	NULL
were	NULL
activated	NULL
with	NULL
anti-CD3	NULL
or	NULL
25	NULL
nM	NULL
of	NULL
ionomycin	NULL
with	NULL
or	NULL
without	NULL
50	NULL
nM	NULL
of	NULL
OAG	NULL
or	NULL
30	NULL
nM	NULL
PMA	NULL
.	NULL

Genomic	NULL
DNA	NULL
fragmentation	NULL
(	NULL
A	NULL
)	NULL
and	NULL
cell	NULL
viability	NULL
(	NULL
B	NULL
)	NULL
were	NULL
assessed	NULL
at	NULL
12	NULL
h	NULL
poststimulation	NULL
.	NULL

A1.1	NULL
cells	NULL
were	NULL
activated	NULL
with	NULL
anti-CD3	NULL
with	NULL
or	NULL
without	NULL
the	NULL
PKC	NULL
inhibitors	NULL
(	NULL
HA	NULL
and	NULL
H7	NULL
,	NULL
50	NULL
uM	NULL
;	NULL
G66976	NULL
,	NULL
1	NULL
uM	NULL
;	NULL
bisindolyImaleimide	NULL
,	NULL
10	NULL
M	NULL
;	NULL
calphostin	NULL
C	NULL
,	NULL
50	NULL
nM	NULL
)	NULL
for	NULL
8	NULL
h.	NULL
Apoptosis	NULL
was	NULL
analyzed	NULL
by	NULL
DNA	NULL
content	NULL
analysis	NULL
(	NULL
C	NULL
)	NULL
and	NULL
genomic	NULL
DNA	NULL
fragmentation	NULL
(	NULL
D	NULL
)	NULL
.	NULL

Different	NULL
isoforms	NULL
of	NULL
PKC	NULL
in	NULL
A1.1	NULL
cells	NULL
were	NULL
determined	NULL
by	NULL
Western	NULL
blot	NULL
analysis	NULL
.	NULL

The	NULL
isoforms	NULL
that	NULL
were	NULL
not	NULL
present	NULL
in	NULL
A1.1	NULL
cells	NULL
were	NULL
underlined	NULL
and	NULL
not	NULL
labeled	NULL
on	NULL
the	NULL
gel	NULL
(	NULL
E	NULL
)	NULL
.	NULL

PMA	NULL
alone	NULL
induces	NULL
Fas	NULL
expression	NULL
We	NULL
have	NULL
reported	NULL
that	NULL
AICD	NULL
in	NULL
T	NULL
cell	NULL
hybridomas	NULL
requires	NULL
de	NULL
novo	NULL
synthesis	NULL
of	NULL
macromolecules	NULL
,	NULL
since	NULL
apoptosis	NULL
could	NULL
be	NULL
suppressed	NULL
by	NULL
the	NULL
inhibition	NULL
of	NULL
either	NULL
protein	NULL
or	NULL
RNA	NULL
synthesis	NULL
(	NULL
15	NULL
)	NULL
.	NULL

However	NULL
,	NULL
recent	NULL
studies	NULL
have	NULL
shown	NULL
that	NULL
the	NULL
apoptosis	NULL
triggered	NULL
by	NULL
anti-Fas	NULL
Ab	NULL
is	NULL
independent	NULL
of	NULL
macromolecular	NULL
synthesis	NULL
once	NULL
the	NULL
Fas	NULL
receptor	NULL
is	NULL
expressed	NULL
(	NULL
22	NULL
)	NULL
.	NULL

Since	NULL
treatment	NULL
with	NULL
phorbol	NULL
esters	NULL
sensitized	NULL
cells	NULL
to	NULL
anti-Fas	NULL
killing	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
,	NULL
the	NULL
effect	NULL
of	NULL
PKC	NULL
activation	NULL
might	NULL
induce	NULL
Fas	NULL
expression	NULL
.	NULL

Therefore	NULL
,	NULL
we	NULL
characterized	NULL
the	NULL
phorbol	NULL
ester	NULL
induction	NULL
of	NULL
Fas	NULL
expression	NULL
.	NULL

A1.1	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
PMA	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
ionomycin	NULL
for	NULL
3	NULL
h	NULL
,	NULL
and	NULL
RNA	NULL
was	NULL
isolated	NULL
.	NULL

Electro-phoretically	NULL
fractionated	NULL
RNA	NULL
was	NULL
examined	NULL
for	NULL
Fas	NULL
and	NULL
FasL	NULL
expression	NULL
by	NULL
Northern	NULL
blot	NULL
hybridization	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Figure	NULL
3A	NULL
,	NULL
the	NULL
expression	NULL
of	NULL
Fas	NULL
mRNA	NULL
could	NULL
be	NULL
induced	NULL
by	NULL
phorbol	NULL
ester	NULL
alone	NULL
,	NULL
whereas	NULL
the	NULL
expression	NULL
of	NULL
FasL	NULL
required	NULL
both	NULL
the	NULL
activation	NULL
of	NULL
PKC	NULL
and	NULL
Ca**	NULL
mobilization	NULL
.	NULL

To	NULL
further	NULL
confirm	NULL
the	NULL
role	NULL
of	NULL
PKC	NULL
activation	NULL
in	NULL
Fas	NULL
expression	NULL
,	NULL
we	NULL
treated	NULL
A1l.1	NULL
cells	NULL
with	NULL
different	NULL
concentrations	NULL
of	NULL
PMA	NULL
(	NULL
0.1	NULL
ng-1000	NULL
ng/m1	NULL
)	NULL
.	NULL

The	NULL
maximal	NULL
induction	NULL
of	NULL
Fas	NULL
expression	NULL
was	NULL
observed	NULL
at	NULL
5	NULL
ng/ml	NULL
.	NULL

The	NULL
expression	NULL
level	NULL
was	NULL
comparable	NULL
with	NULL
the	NULL
level	NULL
induced	NULL
by	NULL
CD3	NULL
ligation	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
)	NULL
.	NULL

On	NULL
the	NULL
other	NULL
hand	NULL
,	NULL
when	NULL
the	NULL
same	NULL
blots	NULL
were	NULL
examined	NULL
for	NULL
the	NULL
expression	NULL
of	NULL
FasL	NULL
,	NULL
we	NULL
found	NULL
that	NULL
PMA	NULL
alone	NULL
does	NULL
not	NULL
have	NULL
any	NULL
effect	NULL
on	NULL
the	NULL
induction	NULL
of	NULL
FasL	NULL
.	NULL

PMA	NULL
plus	NULL
ionomycin	NULL
or	NULL
anti-€CD3	NULL
,	NULL
however	NULL
,	NULL
induced	NULL
the	NULL
expression	NULL
of	NULL
FasL	NULL
.	NULL

Experiments	NULL
with	NULL
OAG	NULL
,	NULL
which	NULL
is	NULL
a	NULL
membrane	NULL
permeable	NULL
analogue	NULL
of	NULL
1,2-diacylglycerol	NULL
(	NULL
32	NULL
)	NULL
,	NULL
showed	NULL
results	NULL
that	NULL
were	NULL
similar	NULL
to	NULL
those	NULL
obtained	NULL
with	NULL
PMA	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

6107	NULL
'01	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
jountwrut	NULL
{	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
;	NULL
A	NULL
FasL+	NULL
FasL-G	NULL
81	NULL
8	NULL
p	NULL
S	NULL
o	NULL
&	NULL
&	NULL
Control	NULL
0	NULL
c	NULL
&	NULL
3	NULL
o	NULL
a	NULL
8	NULL
8	NULL
s	NULL
]	NULL
o	NULL
#	NULL
0	NULL
200	NULL
«	NULL
00	NULL
-	NULL
600	NULL
-	NULL
800	NULL
-	NULL
1000	NULL
0	NULL
200	NULL
-	NULL
400	NULL
600	NULL
800	NULL
-	NULL
1000	NULL
~	NULL
3	NULL
g1	NULL
&	NULL
81	NULL
PMA	NULL
3	NULL
B	NULL
8	NULL
81	NULL
o	NULL
o	NULL
0	NULL
200	NULL
400	NULL
£00	NULL
800	NULL
1000	NULL
0	NULL
200	NULL
400	NULL
600	NULL
800	NULL
1000	NULL
DNA	NULL
Content	NULL
PKC	NULL
MEDIATES	NULL
Fas	NULL
EXPRESSION	NULL
JO2	NULL
No	NULL
JO2	NULL
120	NULL
150	NULL
il	NULL
1	NULL
120	NULL
150	NULL
:	NULL
0	NULL
30	NULL
.	NULL

Control	NULL
0	NULL
60	NULL
1	NULL
30	NULL
30	NULL
i	NULL
600	NULL
soo	NULL
1000	NULL
0	NULL
200	NULL
400	NULL
600	NULL
800	NULL
-	NULL
1000	NULL
o	NULL
200	NULL
400	NULL
150	NULL
h	NULL
150	NULL
i	NULL
120	NULL
90	NULL
OAG	NULL
60	NULL
so	NULL
30	NULL
30	NULL
i	NULL
A0	NULL
zoo	NULL
400	NULL
600	NULL
800	NULL
1000	NULL
0	NULL
200	NULL
400	NULL
600	NULL
800	NULL
1000	NULL
DNA	NULL
Content	NULL
FIGURE	NULL
2	NULL
.	NULL

PKC	NULL
activation	NULL
primes	NULL
T	NULL
cell	NULL
hybridomas	NULL
to	NULL
Fas-mediated	NULL
apoptosis	NULL
.	NULL

A1.1	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
PMA	NULL
(	NULL
30	NULL
nM	NULL
)	NULL
or	NULL
OAG	NULL
(	NULL
50	NULL
nM	NULL
)	NULL
for	NULL
2	NULL
h	NULL
and	NULL
then	NULL
cocultured	NULL
with	NULL
L	NULL
cells	NULL
that	NULL
had	NULL
been	NULL
transfected	NULL
with	NULL
sense	NULL
FasL	NULL
(	NULL
FasL	NULL
*	NULL
)	NULL
or	NULL
antisense	NULL
FasL	NULL
(	NULL
FasL-	NULL
)	NULL
(	NULL
4	NULL
)	NULL
or	NULL
with	NULL
anti-Fas	NULL
(	NULL
JO	NULL
,	NULL
,	NULL
200	NULL
ng/m	NULL
!	NULL
)	NULL

(	NULL
B	NULL
)	NULL
for	NULL
12	NULL
h.	NULL
Apoptosis	NULL
was	NULL
assessed	NULL
by	NULL
cellular	NULL
DNA	NULL
content	NULL
analysis	NULL
.	NULL

Next	NULL
,	NULL
we	NULL
isolated	NULL
RNA	NULL
from	NULL
A1.1	NULL
cells	NULL
that	NULL
had	NULL
been	NULL
treated	NULL
with	NULL
PMA	NULL
for	NULL
different	NULL
times	NULL
;	NULL
we	NULL
found	NULL
that	NULL
the	NULL
PMA-induced	NULL
Fas	NULL
expression	NULL
was	NULL
detectable	NULL
at	NULL
2	NULL
h	NULL
posttreatment	NULL
.	NULL

This	NULL
increase	NULL
was	NULL
sustained	NULL
for	NULL
at	NULL
least	NULL
12	NULL
h	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
while	NULL
the	NULL
Fas	NULL
expression	NULL
that	NULL
was	NULL
induced	NULL
by	NULL
anti-CD3	NULL
diminished	NULL
at	NULL
5	NULL
to	NULL
6	NULL
h	NULL
postactivation	NULL
.	NULL

This	NULL
sustained	NULL
expression	NULL
of	NULL
Fas	NULL
induced	NULL
by	NULL
PMA	NULL
is	NULL
compatible	NULL
with	NULL
the	NULL
extended	NULL
effect	NULL
of	NULL
PMA	NULL
on	NULL
PKC	NULL
activation	NULL
(	NULL
33	NULL
,	NULL
34	NULL
)	NULL
.	NULL

To	NULL
examine	NULL
whether	NULL
the	NULL
activation	NULL
of	NULL
PKC	NULL
alone	NULL
could	NULL
induce	NULL
Fas	NULL
in	NULL
cell	NULL
types	NULL
outside	NULL
the	NULL
T	NULL
cell	NULL
lineage	NULL
,	NULL
we	NULL
treated	NULL
various	NULL
cell	NULL
lines	NULL
with	NULL
PMA	NULL
for	NULL
3	NULL
h	NULL
and	NULL
analyzed	NULL
Fas	NULL
expression	NULL
by	NULL
Northern	NULL
blot	NULL
hybridization	NULL
.	NULL

We	NULL
found	NULL
that	NULL
PMA	NULL
could	NULL
induce	NULL
Fas	NULL
expression	NULL
in	NULL
a	NULL
murine	NULL
B	NULL
cell	NULL
lymphoma	NULL
,	NULL
CH31	NULL
,	NULL
in	NULL
a	NULL
human	NULL
breast	NULL
cancer	NULL
cell	NULL
line	NULL
,	NULL
MDA231	NULL
,	NULL
in	NULL
a	NULL
human	NULL
ovarian	NULL
cancer	NULL
cell	NULL
line	NULL
,	NULL
Hey	NULL
,	NULL
in	NULL
a	NULL
human	NULL
cervical	NULL
cancer	NULL
,	NULL
HeLa	NULL
,	NULL
and	NULL
in	NULL
a	NULL
human	NULL
prostate	NULL
cancer	NULL
,	NULL
DU145	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Since	NULL
it	NULL
has	NULL
recently	NULL
been	NULL
shown	NULL
that	NULL
treating	NULL
Jurkat	NULL
cells	NULL
with	NULL
PMA	NULL
increases	NULL
their	NULL
resistance	NULL
to	NULL
Fas	NULL
ligation-induced	NULL
apoptosis	NULL
(	NULL
34	NULL
)	NULL
,	NULL
we	NULL
have	NULL
tested	NULL
whether	NULL
PMA	NULL
also	NULL
induces	NULL
the	NULL
expression	NULL
of	NULL
Fas	NULL
in	NULL
these	NULL
cells	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Figure	NULL
3C	NULL
,	NULL
we	NULL
found	NULL
indeed	NULL
that	NULL
Jurkat	NULL
cells	NULL
were	NULL
also	NULL
induced	NULL
to	NULL
increase	NULL
the	NULL
expression	NULL
of	NULL
Fas	NULL
.	NULL

Therefore	NULL
,	NULL
the	NULL
effect	NULL
of	NULL
PMA	NULL
on	NULL
the	NULL
sensitivity	NULL
of	NULL
Jurkat	NULL
cells	NULL
to	NULL
Fas-mediated	NULL
apoptosis	NULL
is	NULL
not	NULL
exerted	NULL
by	NULL
regulating	NULL
Fas	NULL
expression	NULL
;	NULL
rather	NULL
the	NULL
effect	NULL
of	NULL
PMA	NULL
is	NULL
exerted	NULL
by	NULL
interfering	NULL
Fas	NULL
signals	NULL
.	NULL

Nevertheless	NULL
,	NULL
our	NULL
results	NULL
in	NULL
A1l.1	NULL
cells	NULL
are	NULL
consistent	NULL
with	NULL
the	NULL
recent	NULL
observation	NULL
of	NULL
Wong	NULL
et	NULL
al	NULL
.	NULL

(	NULL
35	NULL
)	NULL
,	NULL
who	NULL
have	NULL
shown	NULL
that	NULL
PKC	NULL
treatment	NULL
increased	NULL
the	NULL
sensitivity	NULL
of	NULL
T	NULL
cell	NULL
hybridomas	NULL
to	NULL
Fas-mediated	NULL
apoptosis	NULL
(	NULL
the	NULL
double-band	NULL
pattern	NULL
of	NULL
human	NULL
Fas	NULL
has	NULL
been	NULL
shown	NULL
previously	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
PKC	NULL
plays	NULL
a	NULL
general	NULL
role	NULL
in	NULL
regulating	NULL
Fas	NULL
expression	NULL
.	NULL

Expression	NULL
of	NULL
Fas	NULL
is	NULL
completely	NULL
blocked	NULL
by	NULL
PKC	NULL
inhibitors	NULL
Although	NULL
it	NULL
has	NULL
been	NULL
well-established	NULL
that	NULL
the	NULL
activation	NULL
of	NULL
T	NULL
cells	NULL
through	NULL
the	NULL
TCR	NULL
activates	NULL
both	NULL
PKC	NULL
and	NULL
Ca	NULL
``	NULL
*	NULL
influx	NULL
,	NULL
our	NULL
studies	NULL
on	NULL
the	NULL
effect	NULL
of	NULL
activation	NULL
of	NULL
PKC	NULL
with	NULL
PMA	NULL
do	NULL
not	NULL
necessarily	NULL
establish	NULL
a	NULL
physiologic	NULL
role	NULL
for	NULL
PKC	NULL
during	NULL
TCR	NULL
signaling	NULL
.	NULL

To	NULL
confirm	NULL
the	NULL
role	NULL
of	NULL
PKC	NULL
in	NULL
activation-induced	NULL
Fas	NULL
expression	NULL
through	NULL
the	NULL
TCR	NULL
,	NULL
we	NULL
treated	NULL
A1.1	NULL
cells	NULL
with	NULL
anti-CD3	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
the	NULL
PKC	NULL
inhibitor	NULL
,	NULL
H7	NULL
,	NULL
or	NULL
its	NULL
analogue	NULL
,	NULL
HA1OOQ4	NULL
,	NULL
for	NULL
3	NULL
h	NULL
;	NULL
total	NULL
RNA	NULL
was	NULL
isolated	NULL
.	NULL

H-7	NULL
has	NULL
a	NULL
greater	NULL
ability	NULL
to	NULL
inhibit	NULL
PKC	NULL
than	NULL
cyclic	NULL
nucleotide-dependent	NULL
kinase	NULL
.	NULL

Con-versely	NULL
,	NULL
HA1OO4	NULL
has	NULL
a	NULL
greater	NULL
ability	NULL
to	NULL
inhibit	NULL
cyclic	NULL
nucleotide-dependent	NULL
kinase	NULL
than	NULL
PKC	NULL
(	NULL
34	NULL
)	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Figure	NULL
5	NULL
,	NULL
Northern	NULL
blot	NULL
analysis	NULL
revealed	NULL
that	NULL
H7	NULL
completely	NULL
blocked	NULL
activation-induced	NULL
Fas	NULL
expression	NULL
,	NULL
while	NULL
HA1004	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
TCR	NULL
activation-induced	NULL
Fas	NULL
expression	NULL
in	NULL
A1l.1	NULL
cells	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
also	NULL
obtained	NULL
with	NULL
the	NULL
relatively	NULL
specific	NULL
PKC	NULL
inhibitors	NULL
calphostin	NULL
C	NULL
and	NULL
G66983	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Ca	NULL
``	NULL
*	NULL
is	NULL
not	NULL
required	NULL
for	NULL
Fas	NULL
expression	NULL
We	NULL
have	NULL
previously	NULL
reported	NULL
that	NULL
blocking	NULL
Ca*	NULL
-dependent	NULL
calcineurin	NULL
with	NULL
CsA	NULL
completely	NULL
inhibits	NULL
AICD	NULL
in	NULL
T	NULL
cell	NULL
hybridomas	NULL
.	NULL

As	NULL
reported	NULL
recently	NULL
(	NULL
26	NULL
)	NULL
,	NULL
cyclosporin	NULL
could	NULL
inhibit	NULL
activation-induced	NULL
FasL	NULL
but	NULL
not	NULL
Fas	NULL
expression	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

However	NULL
,	NULL
cyclosporin	NULL
has	NULL
no	NULL
effect	NULL
on	NULL
the	NULL
Fas	NULL
expression	NULL
induced	NULL
by	NULL
TCR	NULL
ligation	NULL
or	NULL
PMA	NULL
treatment	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
calcineurin	NULL
and	NULL
downstream	NULL
events	NULL
,	NULL
while	NULL
important	NULL
for	NULL
FasL	NULL
expression	NULL
,	NULL
are	NULL
not	NULL
required	NULL
for	NULL
Fas	NULL
expression	NULL
.	NULL

Since	NULL
cyclosporin	NULL
does	NULL
not	NULL
have	NULL
any	NULL
effect	NULL
on	NULL
cytosolic	NULL
Ca*	NULL
*	NULL
levels	NULL
and	NULL
thus	NULL
does	NULL
not	NULL
interfere	NULL
with	NULL
the	NULL
interaction	NULL
between	NULL
PKC	NULL
and	NULL
Ca**	NULL
,	NULL
we	NULL
tested	NULL
the	NULL
effect	NULL
of	NULL
an	NULL
inhibitor	NULL
of	NULL
intracellular	NULL
Ca**	NULL
redistribution	NULL
,	NULL
TMB-8	NULL
(	NULL
36	NULL
)	NULL
,	NULL
on	NULL
TCR	NULL
cross-linking-induced	NULL
AICD	NULL
.	NULL

We	NULL
found	NULL
that	NULL
TMB-8	NULL
completely	NULL
blocked	NULL
AICD	NULL
(	NULL
Fig	NULL
.	NULL

44	NULL
)	NULL
and	NULL
FasL	NULL
expression	NULL
.	NULL

However	NULL
,	NULL
TMB-8	NULL
did	NULL
not	NULL
inhibit	NULL
the	NULL
activation-induced	NULL
expression	NULL
of	NULL
Fas	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
activation-induced	NULL
Fas	NULL
expression	NULL
is	NULL
independent	NULL
of	NULL
the	NULL
redistribution	NULL
of	NULL
intracellular	NULL
Ca**	NULL
.	NULL

Expression	NULL
of	NULL
Fas	NULL
regulator	NULL
TDAG351	NULL
is	NULL
associated	NULL
with	NULL
Fas	NULL
expression	NULL
PKC	NULL
signaling	NULL
in	NULL
T	NULL
cells	NULL
is	NULL
a	NULL
complex	NULL
process	NULL
involving	NULL
multiple	NULL
enzyme	NULL
cascades	NULL
.	NULL

Although	NULL
our	NULL
data	NULL
clearly	NULL
demonstrated	NULL
6107	NULL
'01	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
jountwrut	NULL
{	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
;	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
A	NULL
Ionomycin+PMA	NULL
|	NULL
|_	NULL
Jer	NULL
Ionomycin	NULL
PMA	NULL
FasL	NULL
|u	NULL
i	NULL
|	NULL
Fas	NULL
~~~	NULL
gump	NULL
Gam	NULL
ene	NULL
B	NULL
2	NULL
%	NULL
I	NULL
,	NULL
%	NULL
z	NULL
&	NULL
2	NULL
3	NULL
-	NULL
m	NULL
#	NULL
wa	NULL
Z	NULL
©	NULL
3	NULL
§	NULL
s	NULL
S	NULL
3	NULL
a	NULL
&	NULL
&	NULL
:	NULL
f	NULL
8	NULL
4	NULL
Gg	NULL
G	NULL
G	NULL
G	NULL
G	NULL
G	NULL
5	NULL
6	NULL
°	NULL
E	NULL
Z	NULL
Z	NULL
£	NULL
£	NULL
Z	NULL
Z	NULL
2	NULL
V	NULL
<	NULL
4	NULL
Cn	NULL
Fa	NULL
Aa	NULL
Pia	NULL
Pa	NULL
C	NULL
C	NULL
Fas	NULL
~	NULL
»	NULL
ap	NULL
os	NULL
wo	NULL
u20De	NULL
©	NULL
TTD	NULL
FasL	NULL
.	NULL

C	NULL
S	NULL
§	NULL
``	NULL
C	NULL
2	NULL
3	NULL
a	NULL
wee	NULL
s	NULL
)	NULL
Po	NULL
go	NULL
f	NULL
5	NULL
Fin	NULL
Ba	NULL
Fag	NULL
s	NULL
caror	NULL
SPP	NULL
Aap	NULL
aah	NULL
FIGURE	NULL
3	NULL
.	NULL

Activation	NULL
of	NULL
PKC	NULL
alone	NULL
induces	NULL
Fas	NULL
expression	NULL
.	NULL

A	NULL
,	NULL
A1.1	NULL
cells	NULL
were	NULL
activated	NULL
with	NULL
PMA	NULL
(	NULL
20	NULL
nM	NULL
)	NULL
or	NULL
PMA	NULL
plus	NULL
ionomycin	NULL
(	NULL
25	NULL
nM	NULL
)	NULL
for	NULL
3	NULL
h.	NULL
The	NULL
expression	NULL
of	NULL
Fas	NULL
and	NULL
FasL	NULL
was	NULL
determined	NULL
by	NULL
Northern	NULL
blot	NULL
.	NULL

B	NULL
,	NULL
Al.1	NULL
cells	NULL
were	NULL
activated	NULL
with	NULL
anti-CD3	NULL
or	NULL
different	NULL
concentrations	NULL
of	NULL
PMA	NULL
for	NULL
3	NULL
h.	NULL
Similarly	NULL
,	NULL
Fas	NULL
and	NULL
FasL	NULL
expression	NULL
was	NULL
examined	NULL
by	NULL
Northern	NULL
blot	NULL
.	NULL

C	NULL
,	NULL
Jurkat	NULL
cells	NULL
were	NULL
activated	NULL
with	NULL
PMA	NULL
.	NULL

The	NULL
expression	NULL
of	NULL
Fas	NULL
was	NULL
accessed	NULL
by	NULL
Northern	NULL
blot	NULL
using	NULL
human	NULL
Fas	NULL
cDNA	NULL
as	NULL
a	NULL
probe	NULL
.	NULL

a	NULL
vital	NULL
role	NULL
for	NULL
PKC	NULL
in	NULL
AICD	NULL
,	NULL
the	NULL
PKC	NULL
downstream	NULL
effectors	NULL
have	NULL
not	NULL
yet	NULL
been	NULL
elucidated	NULL
.	NULL

It	NULL
has	NULL
recently	NULL
been	NULL
reported	NULL
that	NULL
TDAGS51	NULL
,	NULL
a	NULL
newly	NULL
identified	NULL
potential	NULL
transcription	NULL
factor	NULL
,	NULL
is	NULL
required	NULL
for	NULL
activation-induced	NULL
Fas	NULL
expression	NULL
in	NULL
T	NULL
cell	NULL
hybridomas	NULL
(	NULL
17	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
we	NULL
determined	NULL
the	NULL
relationship	NULL
between	NULL
PKC	NULL
and	NULL
TDAGS51	NULL
in	NULL
our	NULL
system	NULL
.	NULL

When	NULL
the	NULL
expression	NULL
of	NULL
TDAGS51	NULL
was	NULL
analyzed	NULL
in	NULL
A1l.1	NULL
cells	NULL
,	NULL
we	NULL
found	NULL
that	NULL
this	NULL
gene	NULL
is	NULL
not	NULL
expressed	NULL
in	NULL
unactivated	NULL
A1l.1	NULL
cells	NULL
.	NULL

However	NULL
,	NULL
its	NULL
expression	NULL
is	NULL
induced	NULL
upon	NULL
activation	NULL
through	NULL
the	NULL
TCR	NULL
or	NULL
by	NULL
PMA	NULL
alone	NULL
.	NULL

Similar	NULL
to	NULL
Fas	NULL
,	NULL
the	NULL
expression	NULL
of	NULL
TDAGS1	NULL
also	NULL
has	NULL
a	NULL
requirement	NULL
for	NULL
PKC	NULL
(	NULL
Fig	NULL
.	NULL

5A	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
we	NULL
examined	NULL
the	NULL
expression	NULL
of	NULL
Fas	NULL
in	NULL
another	NULL
T	NULL
cell	NULL
hybridoma	NULL
,	NULL
KCIT	NULL
,	NULL
and	NULL
its	NULL
mutant	NULL
bearing	NULL
the	NULL
mutation	NULL
of	NULL
TDAGS1	NULL
.	NULL

We	NULL
found	NULL
that	NULL
PMA	NULL
induced	NULL
Fas	NULL
expression	NULL
in	NULL
KCIT	NULL
cells	NULL
,	NULL
but	NULL
not	NULL
in	NULL
the	NULL
TDAGS1	NULL
mutant	NULL
.	NULL

Interestingly	NULL
,	NULL
transfecting	NULL
the	NULL
mutant	NULL
with	NULL
wild-type	NULL
TGAGS1	NULL
restored	NULL
its	NULL
response	NULL
to	NULL
PMA-induced	NULL
Fas	NULL
expression	NULL
(	NULL
Fig	NULL
.	NULL

5B	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
TDAGS1	NULL
is	NULL
a	NULL
downstream	NULL
effector	NULL
in	NULL
the	NULL
PKC-mediated	NULL
pathway	NULL
leading	NULL
to	NULL
the	NULL
induction	NULL
of	NULL
Fas	NULL
expression	NULL
.	NULL

2205	NULL
J	NULL
>	NULL
T	NULL
(	NULL
J	NULL
Control	NULL
MN	NULL
Anti-CD3	NULL
S	NULL
&	NULL
1	NULL
Relative	NULL
Cell	NULL
Viability	NULL
(	NULL
MTT	NULL
,	NULL
O.D	NULL
.	NULL

,	NULL
595	NULL
nM	NULL
,	NULL
Mean	NULL
£	NULL
SE	NULL
)	NULL
re	NULL
tb	NULL
1	NULL
0.0	NULL
'	NULL
TMB-8	NULL
Control	NULL
B	NULL
o	NULL
AZ	NULL
s	NULL
Et	NULL
+	NULL
s	NULL
A	NULL
2	NULL
Wo	NULL
2	NULL
V	NULL
§	NULL
og	NULL
g	NULL
g	NULL
a	NULL
m	NULL
o	NULL
4	NULL
E	NULL
4	NULL
Fas	NULL
|	NULL
®-®	NULL
”	NULL
h	NULL
“	NULL
FasL	NULL
GAPDH	NULL
FIGURE	NULL
4	NULL
.	NULL

-	NULL
Activation-induced	NULL
Fas	NULL
expression	NULL
does	NULL
not	NULL
require	NULL
Ca	NULL
``	NULL
*	NULL
mobilization	NULL
.	NULL

A1.1	NULL
cells	NULL
were	NULL
activated	NULL
with	NULL
anti-CD3	NULL
with	NULL
or	NULL
without	NULL
80	NULL
M	NULL
of	NULL
TMB-8	NULL
.	NULL

Cell	NULL
viability	NULL
was	NULL
determined	NULL
by	NULL
MTT	NULL
assay	NULL
at	NULL
12	NULL
h	NULL
postactivation	NULL
(	NULL
A	NULL
)	NULL
.	NULL

Fas	NULL
and	NULL
FasL	NULL
expression	NULL
was	NULL
determined	NULL
by	NULL
Northern	NULL
blot	NULL
at	NULL
3	NULL
h	NULL
postactivation	NULL
(	NULL
B	NULL
)	NULL
.	NULL

Discussion	NULL
It	NULL
is	NULL
clear	NULL
that	NULL
the	NULL
expression	NULL
of	NULL
Fas	NULL
and	NULL
FasL	NULL
is	NULL
responsible	NULL
for	NULL
apoptosis	NULL
in	NULL
some	NULL
cell	NULL
types	NULL
,	NULL
not	NULL
only	NULL
for	NULL
the	NULL
elimination	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
after	NULL
mounting	NULL
a	NULL
proper	NULL
immune	NULL
response	NULL
(	NULL
12	NULL
,	NULL
37	NULL
)	NULL
but	NULL
also	NULL
for	NULL
the	NULL
maintenance	NULL
of	NULL
immune-privileged	NULL
sites	NULL
(	NULL
38	NULL
,	NULL
39	NULL
)	NULL
.	NULL

AICD	NULL
in	NULL
T	NULL
cells	NULL
requires	NULL
de	NULL
novo	NULL
macromolecular	NULL
synthesis	NULL
,	NULL
including	NULL
the	NULL
up-regulation	NULL
of	NULL
Fas	NULL
and	NULL
FasL	NULL
,	NULL
whose	NULL
interaction	NULL
then	NULL
activates	NULL
the	NULL
apoptosis	NULL
program	NULL
(	NULL
19-21	NULL
)	NULL
.	NULL

Since	NULL
it	NULL
has	NULL
been	NULL
shown	NULL
that	NULL
Fas	NULL
ligation-induced	NULL
apoptosis	NULL
is	NULL
independent	NULL
of	NULL
macromole-cule	NULL
synthesis	NULL
(	NULL
22	NULL
)	NULL
,	NULL
the	NULL
activation	NULL
of	NULL
Fas	NULL
and	NULL
FasL	NULL
genes	NULL
is	NULL
a	NULL
critical	NULL
step	NULL
in	NULL
initiating	NULL
AICD	NULL
.	NULL

It	NULL
has	NULL
been	NULL
well-established	NULL
in	NULL
T	NULL
cell	NULL
hybridomas	NULL
that	NULL
the	NULL
expression	NULL
of	NULL
Fas	NULL
and	NULL
FasL	NULL
increases	NULL
after	NULL
activation	NULL
(	NULL
19	NULL
,	NULL
17	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
blocking	NULL
the	NULL
interaction	NULL
of	NULL
Fas	NULL
and	NULL
FasL	NULL
with	NULL
Fas	NULL
fusion	NULL
proteins	NULL
could	NULL
completely	NULL
block	NULL
AICD	NULL
(	NULL
19	NULL
)	NULL
.	NULL

Alternatively	NULL
,	NULL
T	NULL
cells	NULL
can	NULL
be	NULL
activated	NULL
by	NULL
calcium	NULL
ionophere	NULL
and	NULL
phorbol	NULL
ester	NULL
.	NULL

This	NULL
combination	NULL
implies	NULL
that	NULL
both	NULL
calcium	NULL
redistribution	NULL
and	NULL
the	NULL
translocation	NULL
of	NULL
PKC	NULL
are	NULL
required	NULL
for	NULL
T	NULL
cell	NULL
activation	NULL
(	NULL
30	NULL
)	NULL
.	NULL

Since	NULL
the	NULL
signals	NULL
leading	NULL
to	NULL
the	NULL
expression	NULL
of	NULL
Fas	NULL
still	NULL
remain	NULL
largely	NULL
unknown	NULL
,	NULL
we	NULL
investigated	NULL
the	NULL
role	NULL
of	NULL
Ca**	NULL
and	NULL
PKC	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
Fas	NULL
expression	NULL
.	NULL

Our	NULL
data	NULL
show	NULL
that	NULL
Fas	NULL
expression	NULL
is	NULL
solely	NULL
dependent	NULL
upon	NULL
PKC	NULL
activation	NULL
and	NULL
does	NULL
not	NULL
require	NULL
Ca*	NULL
*	NULL
redistribution	NULL
.	NULL

This	NULL
effect	NULL
of	NULL
PKC	NULL
is	NULL
exerted	NULL
through	NULL
TDAGS1	NULL
.	NULL

PKC-mediated	NULL
Fas	NULL
expression	NULL
was	NULL
also	NULL
observed	NULL
in	NULL
the	NULL
murine	NULL
B	NULL
cell	NULL
lymphoma	NULL
CH31	NULL
and	NULL
in	NULL
several	NULL
human	NULL
cancer	NULL
cell	NULL
6107	NULL
'01	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
jountwrut	NULL
{	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
;	NULL
2206	NULL
Ionomycin	NULL
PMA	NULL
+	NULL
Ionomycin	NULL
Anti-CD3	NULL
+	NULL
H7	NULL
2	NULL
z	NULL
t	NULL
'	NULL
Anti-CD3	NULL
+	NULL
HA	NULL
Anti-CD3	NULL
PMA	NULL
Control	NULL
TDAGS1	NULL
Fas	NULL
|	NULL
»	NULL
«	NULL
»	NULL
~	NULL
>	NULL
with	NULL
s=	NULL
quem	NULL
Garon	NULL
|	NULL
&	NULL
»	NULL
an	NULL
a	NULL
a	NULL
o	NULL
an	NULL
am	NULL
KCIT	NULL
TDAGS1-~/-KCIT	NULL
TDAGS1-/-Transfected	NULL
TDAGS1	NULL
KCIT	NULL
PMA	NULL
-	NULL
t	NULL
=-	NULL
f	NULL
:	NULL
-~	NULL
+	NULL
Fas	NULL
wﬁw	NULL
GAPDH	NULL
FIGURE	NULL
5	NULL
.	NULL

Expression	NULL
of	NULL
TDAGS1	NULL
is	NULL
required	NULL
for	NULL
PKC-mediated	NULL
Fas	NULL
expression	NULL
.	NULL

A	NULL
,	NULL
A1.1	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
PMA	NULL
(	NULL
30	NULL
nM	NULL
)	NULL
with	NULL
or	NULL
without	NULL
ionomycin	NULL
(	NULL
25	NULL
nM	NULL
)	NULL
or	NULL
anti-CD3	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
H7	NULL
or	NULL
HA	NULL
at	NULL
50	NULL
uM	NULL
for	NULL
3	NULL
h.	NULL
The	NULL
expression	NULL
of	NULL
both	NULL
TDAGS1	NULL
and	NULL
Fas	NULL
was	NULL
analyzed	NULL
by	NULL
Northern	NULL
blot	NULL
analysis	NULL
.	NULL

B	NULL
,	NULL
KCIT	NULL
T	NULL
cell	NULL
hybridoma	NULL
,	NULL
its	NULL
TDGA5S1	NULL
mutant	NULL
,	NULL
and	NULL
the	NULL
TDAGS1-transfected	NULL
mutant	NULL
were	NULL
treated	NULL
with	NULL
PMA	NULL
for	NULL
4	NULL
h.	NULL
The	NULL
expression	NULL
of	NULL
Fas	NULL
was	NULL
determined	NULL
by	NULL
Northern	NULL
blot	NULL
analysis	NULL
.	NULL

lines	NULL
.	NULL

Therefore	NULL
,	NULL
PKC	NULL
activation	NULL
may	NULL
be	NULL
a	NULL
critical	NULL
component	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
Fas	NULL
expression	NULL
.	NULL

Recent	NULL
studies	NULL
have	NULL
demonstrated	NULL
that	NULL
FasL	NULL
expression	NULL
could	NULL
be	NULL
inhibited	NULL
by	NULL
CsA	NULL
(	NULL
26	NULL
)	NULL
,	NULL
retinoic	NULL
acid	NULL
(	NULL
40	NULL
)	NULL
,	NULL
antioxidants	NULL
(	NULL
41	NULL
)	NULL
,	NULL
and	NULL
dexamethasone	NULL
(	NULL
42	NULL
)	NULL
.	NULL

In	NULL
accordance	NULL
with	NULL
our	NULL
previous	NULL
results	NULL
on	NULL
the	NULL
requirement	NULL
of	NULL
c-myc	NULL
during	NULL
AICD	NULL
,	NULL
we	NULL
have	NULL
recently	NULL
shown	NULL
that	NULL
the	NULL
inhibition	NULL
of	NULL
c-myc	NULL
expression	NULL
also	NULL
inhibits	NULL
FasL	NULL
expression	NULL
(	NULL
43	NULL
)	NULL
.	NULL

Interestingly	NULL
,	NULL
none	NULL
of	NULL
the	NULL
FasL	NULL
modulatory	NULL
reagents	NULL
had	NULL
any	NULL
effect	NULL
on	NULL
the	NULL
expression	NULL
of	NULL
Fas	NULL
,	NULL
indicating	NULL
that	NULL
the	NULL
expression	NULL
of	NULL
Fas	NULL
and	NULL
FasL	NULL
are	NULL
regulated	NULL
by	NULL
distinct	NULL
pathways	NULL
.	NULL

We	NULL
activated	NULL
A1.1	NULL
cells	NULL
with	NULL
anti-CD3	NULL
Ab-coated	NULL
plastic	NULL
in	NULL
cal-cium-free	NULL
medium	NULL
supplemented	NULL
with	NULL
different	NULL
concentrations	NULL
of	NULL
calcium	NULL
and	NULL
assayed	NULL
DNA	NULL
fragmentation	NULL
at	NULL
12	NULL
h	NULL
poststimulation	NULL
.	NULL

We	NULL
found	NULL
that	NULL
the	NULL
extent	NULL
of	NULL
DNA	NULL
fragmentation	NULL
was	NULL
dependent	NULL
upon	NULL
the	NULL
calcium	NULL
concentration	NULL
in	NULL
the	NULL
medium	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
by	NULL
supplementing	NULL
with	NULL
different	NULL
concentrations	NULL
of	NULL
EGTA	NULL
.	NULL

Thus	NULL
,	NULL
these	NULL
experiments	NULL
clearly	NULL
demonstrated	NULL
that	NULL
extracellular	NULL
Ca**	NULL
is	NULL
essential	NULL
for	NULL
AICD	NULL
in	NULL
the	NULL
T	NULL
cell	NULL
hybridoma	NULL
.	NULL

It	NULL
has	NULL
been	NULL
shown	NULL
that	NULL
the	NULL
blocking	NULL
of	NULL
the	NULL
Ca**	NULL
signal	NULL
by	NULL
CsA	NULL
could	NULL
completely	NULL
inhibit	NULL
FasL	NULL
,	NULL
but	NULL
not	NULL
Fas	NULL
,	NULL
expression	NULL
.	NULL

However	NULL
,	NULL
it	NULL
is	NULL
not	NULL
known	NULL
whether	NULL
Ca**	NULL
alone	NULL
is	NULL
sufficient	NULL
in	NULL
FasL	NULL
induction	NULL
.	NULL

We	NULL
have	NULL
found	NULL
that	NULL
blocking	NULL
intracellular	NULL
Ca**	NULL
with	NULL
TMB-8	NULL
completely	NULL
inhibited	NULL
FasL	NULL
expression	NULL
but	NULL
did	NULL
not	NULL
affect	NULL
Fas	NULL
.	NULL

We	NULL
have	NULL
performed	NULL
experiments	NULL
in	NULL
which	NULL
Al.1	NULL
cells	NULL
were	NULL
PKC	NULL
MEDIATES	NULL
Fas	NULL
EXPRESSION	NULL
treated	NULL
with	NULL
2000	NULL
nM	NULL
of	NULL
PMA	NULL
for	NULL
12	NULL
h.	NULL
We	NULL
found	NULL
that	NULL
this	NULL
treatment	NULL
blocked	NULL
activation-induced	NULL
apoptosis	NULL
in	NULL
these	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Although	NULL
this	NULL
treatment	NULL
blocked	NULL
activation-induced	NULL
FasL	NULL
expression	NULL
,	NULL
it	NULL
did	NULL
not	NULL
show	NULL
effects	NULL
on	NULL
Fas	NULL
expression	NULL
.	NULL

Since	NULL
the	NULL
Ca**	NULL
PKC	NULL
isoforms	NULL
are	NULL
more	NULL
sensitive	NULL
to	NULL
PMA	NULL
depletion	NULL
,	NULL
we	NULL
conclude	NULL
that	NULL
activation-induced	NULL
Fas	NULL
expression	NULL
does	NULL
not	NULL
require	NULL
Ca*	NULL
*	NULL
based	NULL
on	NULL
these	NULL
findings	NULL
and	NULL
the	NULL
above	NULL
data	NULL
combined	NULL
with	NULL
our	NULL
observation	NULL
that	NULL
PMA	NULL
alone	NULL
could	NULL
induce	NULL
maximal	NULL
Fas	NULL
expression	NULL
.	NULL

Thus	NULL
,	NULL
our	NULL
data	NULL
strongly	NULL
suggest	NULL
that	NULL
FasL	NULL
expression	NULL
requires	NULL
both	NULL
PKC	NULL
and	NULL
Ca**	NULL
.	NULL

We	NULL
have	NULL
shown	NULL
that	NULL
the	NULL
diacylglycerol	NULL
analogue	NULL
OAG	NULL
,	NULL
which	NULL
stimulates	NULL
PKC	NULL
,	NULL
induces	NULL
apoptosis	NULL
in	NULL
A1l.1	NULL
cells	NULL
when	NULL
added	NULL
together	NULL
with	NULL
ionomycin	NULL
.	NULL

Further	NULL
,	NULL
we	NULL
have	NULL
shown	NULL
that	NULL
the	NULL
inhibition	NULL
of	NULL
PKC	NULL
could	NULL
prevent	NULL
activation	NULL
and	NULL
inhibit	NULL
anti-CD3-induced	NULL
Fas	NULL
expression	NULL
and	NULL
apoptosis	NULL
in	NULL
the	NULL
T	NULL
cell	NULL
hybridoma	NULL
.	NULL

This	NULL
observation	NULL
indicates	NULL
that	NULL
PKC	NULL
is	NULL
involved	NULL
in	NULL
activation-induced	NULL
Fas	NULL
expression	NULL
.	NULL

When	NULL
we	NULL
down-regulated	NULL
PKC	NULL
function	NULL
by	NULL
preincubating	NULL
cells	NULL
with	NULL
high	NULL
concentrations	NULL
of	NULL
PMA	NULL
,	NULL
we	NULL
were	NULL
able	NULL
to	NULL
show	NULL
again	NULL
that	NULL
activation-induced	NULL
Fas	NULL
expression	NULL
required	NULL
PKC	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

TDAGS1	NULL
is	NULL
a	NULL
newly	NULL
identified	NULL
potential	NULL
transcription	NULL
factor	NULL
that	NULL
is	NULL
involved	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
activation-induced	NULL
Fas	NULL
expression	NULL
in	NULL
the	NULL
T	NULL
hybridoma	NULL
KMIs-8.3.5	NULL
.	NULL

This	NULL
hybridoma	NULL
undergoes	NULL
Fas/	NULL
FasL-dependent	NULL
apoptosis	NULL
upon	NULL
activation	NULL
.	NULL

A	NULL
variant	NULL
of	NULL
KMIs-8.3.5	NULL
bearing	NULL
a	NULL
mutation	NULL
in	NULL
TDAGS1	NULL
expresses	NULL
FasL	NULL
,	NULL
TNFR-1	NULL
,	NULL
and	NULL
IL-2	NULL
,	NULL
but	NULL
not	NULL
Fas	NULL
(	NULL
17	NULL
)	NULL
.	NULL

Transfection	NULL
of	NULL
the	NULL
active	NULL
gene	NULL
restored	NULL
activation-induced	NULL
Fas	NULL
expression	NULL
in	NULL
this	NULL
mutant	NULL
.	NULL

Thus	NULL
,	NULL
TDAGS1	NULL
may	NULL
play	NULL
an	NULL
essential	NULL
role	NULL
in	NULL
the	NULL
induction	NULL
of	NULL
apoptosis	NULL
by	NULL
coupling	NULL
TCR	NULL
stimulation	NULL
to	NULL
Fas	NULL
expression	NULL
.	NULL

Our	NULL
data	NULL
show	NULL
that	NULL
TDAGS1	NULL
expression	NULL
could	NULL
also	NULL
be	NULL
activated	NULL
solely	NULL
by	NULL
PKC	NULL
;	NULL
it	NULL
is	NULL
very	NULL
likely	NULL
that	NULL
the	NULL
effect	NULL
of	NULL
TDAGS1	NULL
acts	NULL
downstream	NULL
of	NULL
PKC	NULL
.	NULL

How	NULL
TDAGS1	NULL
regulates	NULL
Fas	NULL
expression	NULL
is	NULL
currently	NULL
not	NULL
known	NULL
.	NULL

The	NULL
transfection	NULL
of	NULL
TDAGS1	NULL
does	NULL
not	NULL
appear	NULL
to	NULL
induce	NULL
Fas	NULL
expression	NULL
(	NULL
17	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
it	NULL
is	NULL
possible	NULL
that	NULL
other	NULL
factors	NULL
are	NULL
required	NULL
.	NULL

Studies	NULL
are	NULL
in	NULL
progress	NULL
to	NULL
determine	NULL
how	NULL
PKC	NULL
regulates	NULL
TDAGS1	NULL
and	NULL
Fas	NULL
expression	NULL
.	NULL

Acknowledgments	NULL
We	NULL
thank	NULL
Drs	NULL
.	NULL

David	NULL
W.	NULL
Scott	NULL
,	NULL
Wendy	NULL
Davidson	NULL
,	NULL
Achsah	NULL
D.	NULL
Keegan	NULL
,	NULL
and	NULL
Juliann	NULL
G.	NULL
Kiang	NULL
for	NULL
critical	NULL
discussions	NULL
.	NULL

This	NULL
is	NULL
publication	NULL
number	NULL
46	NULL
of	NULL
the	NULL
Department	NULL
of	NULL
Immunology	NULL
,	NULL
Holland	NULL
Laboratory	NULL
.	NULL

References	NULL
1	NULL
.	NULL

Qian	NULL
,	NULL
D.	NULL
,	NULL
and	NULL
A.	NULL
Weiss	NULL
.	NULL

1997	NULL
.	NULL

T	NULL
cell	NULL
antigen	NULL
receptor	NULL
signal	NULL
transduction	NULL
.	NULL

Curr	NULL
.	NULL

Opin	NULL
.	NULL

Cell	NULL
Biol	NULL
.	NULL

9:205	NULL
.	NULL

2	NULL
.	NULL

Cantrell	NULL
,	NULL
D.	NULL
A	NULL
.	NULL

1996	NULL
.	NULL

T	NULL
cell	NULL
antigen	NULL
receptor	NULL
signal	NULL
transduction	NULL
pathways	NULL
.	NULL

Cancer	NULL
Surv	NULL
.	NULL

27:165	NULL
.	NULL

3	NULL
.	NULL

Bochmer	NULL
von	NULL
,	NULL
H.	NULL
,	NULL
and	NULL
H.	NULL
J.	NULL
Fehling	NULL
.	NULL

1997	NULL
.	NULL

Structure	NULL
and	NULL
function	NULL
of	NULL
the	NULL
pre-T	NULL
cell	NULL
receptor	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

15:433	NULL
.	NULL

4	NULL
.	NULL

Chambers	NULL
,	NULL
C.	NULL
A.	NULL
,	NULL
and	NULL
J.	NULL
P.	NULL
Allison	NULL
.	NULL

1997	NULL
.	NULL

Co-stimulation	NULL
in	NULL
T	NULL
cell	NULL
responses	NULL
.	NULL

Curr	NULL
.	NULL

Opin	NULL
.	NULL

Immunol	NULL
.	NULL

9:396	NULL
.	NULL

5	NULL
.	NULL

Smith	NULL
,	NULL
C.	NULL
A.	NULL
,	NULL
G.	NULL
T.	NULL
Williams	NULL
,	NULL
R.	NULL
Kingston	NULL
,	NULL
E.	NULL
J.	NULL
Jenkinson	NULL
,	NULL
and	NULL
J.	NULL
J.	NULL
Owen	NULL
.	NULL

1989	NULL
.	NULL

Antibodies	NULL
to	NULL
CD3/T-cell	NULL
receptor	NULL
complex	NULL
induce	NULL
death	NULL
by	NULL
apoptosis	NULL
in	NULL
immature	NULL
T	NULL
cells	NULL
in	NULL
thymic	NULL
cultures	NULL
.	NULL

Nature	NULL
337:181	NULL
.	NULL

6	NULL
.	NULL

Shi	NULL
,	NULL
Y.	NULL
F.	NULL
,	NULL
B.	NULL
M.	NULL
Sahai	NULL
,	NULL
and	NULL
D.	NULL
R.	NULL
Green	NULL
.	NULL

1989	NULL
.	NULL

Cyclosporin	NULL
A	NULL
inhibits	NULL
activation-induced	NULL
cell	NULL
death	NULL
in	NULL
T-cell	NULL
hybridomas	NULL
and	NULL
thymocytes	NULL
.	NULL

Nature	NULL
339:625	NULL
.	NULL

7	NULL
.	NULL

Murphy	NULL
,	NULL
K.	NULL
M.	NULL
,	NULL
A	NULL
.	NULL

B.	NULL
Heimberger	NULL
,	NULL
and	NULL
D.	NULL
Y.	NULL
Loh	NULL
.	NULL

1991	NULL
.	NULL

Induction	NULL
by	NULL
antigen	NULL
of	NULL
intrathymic	NULL
apoptosis	NULL
of	NULL
CD4*CD8*	NULL
thymocytes	NULL
in	NULL
vivo	NULL
.	NULL

Science	NULL
250:1720	NULL
.	NULL

8	NULL
.	NULL

Russell	NULL
,	NULL
J.	NULL
H.	NULL
,	NULL
C.	NULL
L.	NULL
White	NULL
,	NULL
D.	NULL
Y.	NULL
Loh	NULL
,	NULL
and	NULL
P.	NULL
Meleedy-Rey	NULL
.	NULL

1991	NULL
.	NULL

Receptor-stimulated	NULL
death	NULL
pathway	NULL
is	NULL
opened	NULL
by	NULL
antigen	NULL
in	NULL
mature	NULL
T	NULL
cells	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
88:2151	NULL
.	NULL

9	NULL
.	NULL

Lenardo	NULL
,	NULL
M.	NULL
J	NULL
.	NULL

1991	NULL
.	NULL

Interleukin-2	NULL
programs	NULL
mouse	NULL
af	NULL
T	NULL
lymphocytes	NULL
for	NULL
apoptosis	NULL
.	NULL

Nature	NULL
353:858	NULL
.	NULL

10	NULL
.	NULL

Radvanyi	NULL
,	NULL
L.	NULL
G.	NULL
,	NULL
G.	NULL
B	NULL
.	NULL

Mills	NULL
,	NULL
and	NULL
R.	NULL
G.	NULL
Miller	NULL
.	NULL

1993	NULL
.	NULL

Religation	NULL
of	NULL
the	NULL
T	NULL
cell	NULL
receptor	NULL
after	NULL
primary	NULL
activation	NULL
of	NULL
mature	NULL
T	NULL
cells	NULL
inhibits	NULL
proliferation	NULL
and	NULL
induces	NULL
apoptotic	NULL
cell	NULL
death	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

150:5704	NULL
.	NULL

11	NULL
.	NULL

Ameisen	NULL
,	NULL
J.	NULL
C.	NULL
,	NULL
and	NULL
A.	NULL
Capron	NULL
.	NULL

1991	NULL
.	NULL

Cell	NULL
dysfunction	NULL
and	NULL
depletion	NULL
in	NULL
AIDS	NULL
:	NULL
the	NULL
programmed	NULL
cell	NULL
death	NULL
hypothesis	NULL
.	NULL

Immunol	NULL
.	NULL

Today	NULL
12:102	NULL
.	NULL

12	NULL
.	NULL

Tsokos	NULL
G.	NULL
C.	NULL
,	NULL
B.	NULL
Kovacs	NULL
,	NULL
and	NULL
S.	NULL
N.	NULL
Liossis	NULL
.	NULL

1997	NULL
.	NULL

Lymphocytes	NULL
,	NULL
cytokines	NULL
,	NULL
inflammation	NULL
,	NULL
and	NULL
immune	NULL
trafficking	NULL
.	NULL

Curr	NULL
.	NULL

Opin	NULL
.	NULL

Rheumatol	NULL
.	NULL

9:380	NULL
.	NULL

6107	NULL
'01	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
jountwrut	NULL
{	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
;	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

Berridge	NULL
,	NULL
M.	NULL
J	NULL
.	NULL

1997	NULL
.	NULL

Lymphocyte	NULL
activation	NULL
in	NULL
health	NULL
and	NULL
disease	NULL
.	NULL

Crit	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

17:155	NULL
.	NULL

Mercep	NULL
,	NULL
M.	NULL
,	NULL
P.	NULL
D.	NULL
Noguchi	NULL
,	NULL
and	NULL
J.	NULL
D.	NULL
Ashwell	NULL
.	NULL

1989	NULL
.	NULL

The	NULL
cell	NULL
cycle	NULL
block	NULL
and	NULL
lysis	NULL
of	NULL
an	NULL
activated	NULL
T	NULL
cell	NULL
hybridoma	NULL
are	NULL
distinct	NULL
processes	NULL
with	NULL
different	NULL
Ca**	NULL
requirements	NULL
and	NULL
sensitivity	NULL
to	NULL
cyclosporin	NULL
A.	NULL
J.	NULL
Immunol	NULL
.	NULL

142:4085	NULL
.	NULL

Shi	NULL
,	NULL
Y.	NULL
,	NULL
M.	NULL
G.	NULL
Szalay	NULL
,	NULL
L.	NULL
Paskar	NULL
,	NULL
M.	NULL
Boyer	NULL
,	NULL
B.	NULL
Singh	NULL
,	NULL
and	NULL
D.	NULL
R.	NULL
Green	NULL
.	NULL

1990	NULL
.	NULL

Activation-induced	NULL
cell	NULL
death	NULL
in	NULL
T	NULL
cell	NULL
hybridoma	NULL
is	NULL
due	NULL
to	NULL
apoptosis	NULL
:	NULL
morphological	NULL
aspects	NULL
and	NULL
DNA	NULL
fragmentation	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

144:3326	NULL
.	NULL

Liu	NULL
,	NULL
Z.	NULL
G.	NULL
,	NULL
S.	NULL
W.	NULL
Smith	NULL
,	NULL
K.	NULL
A.	NULL
McLaughlin	NULL
,	NULL
L.	NULL
M.	NULL
Schwartz	NULL
,	NULL
and	NULL
B	NULL
.	NULL

A.	NULL
Osborne	NULL
.	NULL

1994	NULL
.	NULL

Apoptotic	NULL
signals	NULL
delivered	NULL
through	NULL
the	NULL
T-cell	NULL
receptor	NULL
of	NULL
a	NULL
T-cell	NULL
hybrid	NULL
require	NULL
the	NULL
immediate-early	NULL
gene	NULL
nur77	NULL
.	NULL

Nature	NULL
367:281	NULL
.	NULL

Park	NULL
,	NULL
C.	NULL
G.	NULL
,	NULL
S.	NULL
Y.	NULL
Lee	NULL
,	NULL
G.	NULL
Kandala	NULL
,	NULL
and	NULL
Y.	NULL
Choi	NULL
.	NULL

1996	NULL
.	NULL

A	NULL
novel	NULL
gene	NULL
product	NULL
that	NULL
couples	NULL
TCR	NULL
signaling	NULL
to	NULL
Fas	NULL
(	NULL
CD95	NULL
)	NULL
expression	NULL
in	NULL
activation-induced	NULL
cell	NULL
death	NULL
.	NULL

Immunity	NULL
4:583	NULL
.	NULL

Nagata	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
T.	NULL
Suda	NULL
.	NULL

1995	NULL
.	NULL

Fas	NULL
and	NULL
Fas	NULL
ligand	NULL
:	NULL
Ipr	NULL
and	NULL
g/d	NULL
mutations	NULL
.	NULL

Immunol	NULL
.	NULL

Today	NULL
16:39	NULL
.	NULL

Brunner	NULL
,	NULL
T.	NULL
,	NULL
R.	NULL
J.	NULL
Mogil	NULL
,	NULL
D.	NULL
LaFace	NULL
,	NULL
N.	NULL
J.	NULL
Yoo	NULL
,	NULL
A.	NULL
Mahboubi	NULL
,	NULL
F.	NULL
Echeverri	NULL
,	NULL
S.	NULL
J.	NULL
Martin	NULL
,	NULL
W.	NULL
R.	NULL
Force	NULL
,	NULL
D.	NULL
H.	NULL
Lynch	NULL
,	NULL
C.	NULL
F.	NULL
Ware	NULL
,	NULL
and	NULL
D.	NULL
R.	NULL
Green	NULL
.	NULL

1995	NULL
.	NULL

Cell-autonomous	NULL
Fas	NULL
(	NULL
CD95	NULL
)	NULL
/Fas-ligand	NULL
interaction	NULL
mediates	NULL
activation-induced	NULL
apoptosis	NULL
in	NULL
T-cell	NULL
hybridomas	NULL
.	NULL

Nature	NULL
373:441	NULL
.	NULL

Ju	NULL
,	NULL
S.	NULL
T.	NULL
,	NULL
D.	NULL
J.	NULL
Panka	NULL
,	NULL
H.	NULL
Cui	NULL
,	NULL
R.	NULL
Ettinger	NULL
,	NULL
M.	NULL
el-Khatib	NULL
,	NULL
D.	NULL
H.	NULL
Sherr	NULL
,	NULL
B	NULL
.	NULL

Z.	NULL
Stanger	NULL
,	NULL
and	NULL
A.	NULL
Marshak-Rothstein	NULL
.	NULL

1995	NULL
.	NULL

Fas	NULL
(	NULL
CD95	NULL
)	NULL
/FasL	NULL
interactions	NULL
required	NULL
for	NULL
programmed	NULL
cell	NULL
death	NULL
after	NULL
T-cell	NULL
activation	NULL
.	NULL

Nature	NULL
373:444	NULL
.	NULL

Nagata	NULL
,	NULL
S.	NULL
1996	NULL
.	NULL

Apoptosis	NULL
mediated	NULL
by	NULL
the	NULL
Fas	NULL
system	NULL
.	NULL

Prog	NULL
.	NULL

Mol	NULL
.	NULL

Subcell	NULL
.	NULL

Biol	NULL
.	NULL

16:87	NULL
.	NULL

Anderson	NULL
,	NULL
K.	NULL
L.	NULL
,	NULL
G.	NULL
Anderson	NULL
,	NULL
R.	NULL
H.	NULL
Michell	NULL
,	NULL
E.	NULL
J.	NULL
Jenkinson	NULL
,	NULL
and	NULL
J.	NULL
J.	NULL
Owen	NULL
.	NULL

1996	NULL
.	NULL

Intracellular	NULL
signaling	NULL
pathways	NULL
involved	NULL
in	NULL
the	NULL
induction	NULL
of	NULL
apoptosis	NULL
in	NULL
immature	NULL
thymic	NULL
T	NULL
lymphocytes	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

156:4083	NULL
.	NULL

Depractere	NULL
,	NULL
V.	NULL
,	NULL
and	NULL
P.	NULL
Golstein	NULL
.	NULL

1997	NULL
.	NULL

Fas	NULL
and	NULL
other	NULL
cell	NULL
death-signaling	NULL
pathways	NULL
.	NULL

Semin	NULL
.	NULL

Immunol	NULL
.	NULL

9:93	NULL
.	NULL

Keane	NULL
,	NULL
M.	NULL
M.	NULL
,	NULL
S.	NULL
A.	NULL
Ettenberg	NULL
,	NULL
G.	NULL
A.	NULL
Lowrey	NULL
,	NULL
E.	NULL
K.	NULL
Russell	NULL
,	NULL
and	NULL
S.	NULL
Lipkowitz	NULL
.	NULL

1996	NULL
.	NULL

Fas	NULL
expression	NULL
and	NULL
function	NULL
in	NULL
normal	NULL
and	NULL
malignant	NULL
breast	NULL
cell	NULL
lines	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

56:4791	NULL
.	NULL

Owen-Schaub	NULL
,	NULL
L.	NULL
B.	NULL
,	NULL
W.	NULL
Zhang	NULL
,	NULL
J.	NULL
C.	NULL
Cusack	NULL
,	NULL
L.	NULL
S.	NULL
Angelo	NULL
,	NULL
S.	NULL
M.	NULL
Santee	NULL
,	NULL
T.	NULL
Fujiwara	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Roth	NULL
,	NULL
and	NULL
A.	NULL
Deisseroth	NULL
.	NULL

1995	NULL
.	NULL

Wild-type	NULL
human	NULL
p53	NULL
and	NULL
a	NULL
temperature-sensitive	NULL
mutant	NULL
induce	NULL
Fas/APO-1	NULL
expression	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

15	NULL
:	NULL
3032	NULL
.	NULL

Brunner	NULL
,	NULL
T.	NULL
,	NULL
N.	NULL
J.	NULL
Yoo	NULL
,	NULL
D.	NULL
LaFace	NULL
,	NULL
C.	NULL
F.	NULL
Ware	NULL
,	NULL
and	NULL
D.	NULL
R.	NULL
Green	NULL
.	NULL

1996	NULL
.	NULL

Activation-induced	NULL
cell	NULL
death	NULL
in	NULL
murine	NULL
T	NULL
cell	NULL
hybridomas	NULL
:	NULL
differential	NULL
regulation	NULL
of	NULL
Fas	NULL
(	NULL
CD95	NULL
)	NULL
versus	NULL
Fas	NULL
ligand	NULL
expression	NULL
by	NULL
cyclosporin	NULL
A	NULL
and	NULL
FK506	NULL
.	NULL

Int	NULL
.	NULL

Immunol	NULL
.	NULL

8:1017	NULL
.	NULL

Fotedar	NULL
,	NULL
A.	NULL
,	NULL
M.	NULL
Boyer	NULL
,	NULL
W.	NULL
Smart	NULL
,	NULL
J.	NULL
Widtman	NULL
,	NULL
E.	NULL
Fraga	NULL
,	NULL
and	NULL
B.	NULL
Singh	NULL
.	NULL

1985	NULL
.	NULL

Fine	NULL
specificity	NULL
of	NULL
antigen	NULL
recognition	NULL
by	NULL
T	NULL
cell	NULL
hybridoma	NULL
clone	NULL
specific	NULL
for	NULL
poly18	NULL
:	NULL
28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

2207	NULL
a	NULL
synthetic	NULL
polypeptide	NULL
of	NULL
defined	NULL
sequence	NULL
and	NULL
conformation	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

135	NULL
:	NULL
3028	NULL
.	NULL

Nicoletti	NULL
,	NULL
I.	NULL
,	NULL
G.	NULL
Migliorati	NULL
,	NULL
M.	NULL
C.	NULL
Pagliacci	NULL
,	NULL
F.	NULL
Grignani	NULL
,	NULL
and	NULL
C.	NULL
Riccardi	NULL
.	NULL

1991	NULL
.	NULL

A	NULL
rapid	NULL
and	NULL
simple	NULL
method	NULL
for	NULL
measuring	NULL
thymocyte	NULL
apoptosis	NULL
by	NULL
propidium	NULL
iodide	NULL
staining	NULL
and	NULL
flow	NULL
cytometry	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

Methods	NULL
139:271	NULL
.	NULL

Mosmann	NULL
,	NULL
T.	NULL
1983	NULL
.	NULL

Rapid	NULL
colorimetric	NULL
assay	NULL
for	NULL
cellular	NULL
growth	NULL
and	NULL
survival	NULL
:	NULL
application	NULL
to	NULL
proliferation	NULL
and	NULL
cytotoxicity	NULL
assays	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

Methods	NULL
65:55	NULL
.	NULL

Gelfand	NULL
,	NULL
E.	NULL
W.	NULL
,	NULL
G.	NULL
B	NULL
.	NULL

Mills	NULL
,	NULL
R.	NULL
K.	NULL
Cheung	NULL
,	NULL
J.	NULL
W.	NULL
Lee	NULL
and	NULL
S.	NULL
Grinstein	NULL
.	NULL

1987	NULL
.	NULL

Transmembrane	NULL
ion	NULL
fluxes	NULL
during	NULL
activation	NULL
of	NULL
human	NULL
T	NULL
lymphocytes	NULL
:	NULL
role	NULL
of	NULL
Ca	NULL
``	NULL
Na	NULL
*/H*	NULL
exchange	NULL
and	NULL
phospholipid	NULL
turnover	NULL
.	NULL

Immunol	NULL
.	NULL

Rev	NULL
.	NULL

95:59	NULL
.	NULL

Liu	NULL
,	NULL
J.	NULL
P.	NULL
1996	NULL
.	NULL

Protein	NULL
kinase	NULL
C	NULL
and	NULL
its	NULL
substrates	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Endocrinol	NULL
.	NULL

116:1	NULL
.	NULL

Seibicke	NULL
,	NULL
S.	NULL
,	NULL
J	NULL
.	NULL

B.	NULL
Strosznajder	NULL
,	NULL
and	NULL
E.	NULL
W.	NULL
Hacffner	NULL
.	NULL

1988	NULL
.	NULL

Differential	NULL
effect	NULL
on	NULL
inositol-phospholipid	NULL
hydrolysis	NULL
,	NULL
cytosolic-free	NULL
Ca**	NULL
concentration	NULL
,	NULL
protein	NULL
kinase	NULL
C	NULL
activity	NULL
,	NULL
and	NULL
protein	NULL
phosphorylation	NULL
of	NULL
l-oleoyl-2-acetyl-sn-glycerol	NULL
growth-stimulated	NULL
ascites	NULL
tumor	NULL
cells	NULL
.	NULL

Eur	NULL
.	NULL

J	NULL
.	NULL

Cell	NULL
Biol	NULL
.	NULL

46:403	NULL
.	NULL

Blobe	NULL
,	NULL
G.	NULL
C.	NULL
,	NULL
S.	NULL
Stribling	NULL
,	NULL
L.	NULL
M.	NULL
Obeid	NULL
,	NULL
and	NULL
Y	NULL
.	NULL

A.	NULL
Hannun	NULL
.	NULL

1996	NULL
.	NULL

Protein	NULL
kinase	NULL
C	NULL
isoenzymes	NULL
:	NULL
regulation	NULL
and	NULL
function	NULL
.	NULL

Cancer	NULL
Surv	NULL
.	NULL

27:213	NULL
.	NULL

Ruiz-Ruiz	NULL
,	NULL
M.	NULL
C.	NULL
,	NULL
M.	NULL
Izquierdo	NULL
,	NULL
G.	NULL
de	NULL
Murcia	NULL
,	NULL
and	NULL
A.	NULL
Lopez-Rivas	NULL
.	NULL

1997	NULL
.	NULL

Activation	NULL
of	NULL
protein	NULL
kinase	NULL
C	NULL
attenuates	NULL
carly	NULL
signals	NULL
in	NULL
Fas-mediated	NULL
apoptosis	NULL
.	NULL

Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

27:1442	NULL
.	NULL

Wong	NULL
B.	NULL
,	NULL
J.	NULL
Arron	NULL
,	NULL
and	NULL
Y.	NULL
Choi	NULL
.	NULL

1997	NULL
.	NULL

T	NULL
cell	NULL
receptor	NULL
signals	NULL
enhance	NULL
susceptibility	NULL
to	NULL
Fas-mediated	NULL
apoptosis	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

186:1939	NULL
.	NULL

Grier	NULL
,	NULL
C.	NULL
E.	NULL
,	NULL
and	NULL
A.	NULL
M.	NULL
Mastro	NULL
.	NULL

1985	NULL
.	NULL

Mitogen	NULL
and	NULL
co-mitogen	NULL
stimulation	NULL
of	NULL
lymphocytes	NULL
inhibited	NULL
by	NULL
three	NULL
Ca	NULL
**	NULL
antagonists	NULL
.	NULL

J	NULL
.	NULL

Cell	NULL
.	NULL

Physiol	NULL
.	NULL

124:131	NULL
.	NULL

Winoto	NULL
,	NULL
A	NULL
.	NULL

1997	NULL
.	NULL

Cell	NULL
death	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
immune	NULL
responses	NULL
.	NULL

Curr	NULL
.	NULL

Opin	NULL
.	NULL

Immunol	NULL
.	NULL

9:365	NULL
.	NULL

Beligrau	NULL
,	NULL
D.	NULL
,	NULL
D.	NULL
Gold	NULL
,	NULL
H.	NULL
Selawry	NULL
,	NULL
J.	NULL
Moore	NULL
,	NULL
A.	NULL
Franzusoff	NULL
,	NULL
and	NULL
R.	NULL
C.	NULL
Duke	NULL
.	NULL

1995	NULL
.	NULL

A	NULL
role	NULL
for	NULL
CD95	NULL
ligand	NULL
in	NULL
preventing	NULL
graft	NULL
rejection	NULL
.	NULL

Nature	NULL
377:6550	NULL
.	NULL

Griffith	NULL
,	NULL
T.	NULL
S.	NULL
,	NULL
T.	NULL
Brunner	NULL
,	NULL
S.	NULL
M.	NULL
Fletcher	NULL
,	NULL
D.	NULL
R.	NULL
Green	NULL
,	NULL
and	NULL
T.	NULL
A.	NULL
Ferguson	NULL
.	NULL

1995	NULL
.	NULL

Fas	NULL
ligand-induced	NULL
apoptosis	NULL
as	NULL
a	NULL
mechanism	NULL
of	NULL
immune	NULL
privilege	NULL
.	NULL

Science	NULL
270	NULL
:	NULL
5239	NULL
.	NULL

Bissonnette	NULL
,	NULL
R.	NULL
P.	NULL
,	NULL
T.	NULL
Brunner	NULL
,	NULL
S.	NULL
B.	NULL
Lazarchik	NULL
,	NULL
N.	NULL
J.	NULL
Yoo	NULL
,	NULL
M.	NULL
F.	NULL
Bochm	NULL
,	NULL
D.	NULL
R.	NULL
Green	NULL
,	NULL
and	NULL
R.	NULL
A.	NULL
Heyman	NULL
.	NULL

1995	NULL
.	NULL

9-cis	NULL
retinoic	NULL
acid	NULL
inhibition	NULL
of	NULL
activation-induced	NULL
apoptosis	NULL
is	NULL
mediated	NULL
via	NULL
regulation	NULL
of	NULL
Fas	NULL
ligand	NULL
and	NULL
requires	NULL
retinoic	NULL
acid	NULL
receptor	NULL
and	NULL
retinoid	NULL
X	NULL
receptor	NULL
activation	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

15:5576	NULL
.	NULL

Williams	NULL
,	NULL
M.	NULL
S.	NULL
,	NULL
and	NULL
P.	NULL
A.	NULL
Henkart	NULL
.	NULL

1996	NULL
.	NULL

Role	NULL
of	NULL
reactive	NULL
oxygen	NULL
intermediates	NULL
in	NULL
TCR-induced	NULL
death	NULL
of	NULL
T	NULL
cell	NULL
blasts	NULL
and	NULL
hybridomas	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

157:2395	NULL
.	NULL

Yang	NULL
,	NULL
Y.	NULL
,	NULL
M.	NULL
Mercep	NULL
,	NULL
C.	NULL
F.	NULL
Ware	NULL
,	NULL
and	NULL
J.	NULL
D.	NULL
Ashwell	NULL
.	NULL

1995	NULL
.	NULL

Fas	NULL
and	NULL
activation-induced	NULL
Fas	NULL
ligand	NULL
mediate	NULL
apoptosis	NULL
of	NULL
T	NULL
cell	NULL
hybridomas	NULL
:	NULL
inhibition	NULL
of	NULL
Fas	NULL
ligand	NULL
expression	NULL
by	NULL
retinoic	NULL
acid	NULL
and	NULL
glucocorticoids	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

181:1673	NULL
.	NULL

Wang	NULL
,	NULL
R.	NULL
X.	NULL
,	NULL
T.	NULL
Brunner	NULL
,	NULL
L.	NULL
Zhang	NULL
,	NULL
and	NULL
Y.	NULL
F.	NULL
Shi	NULL
.	NULL

1998	NULL
.	NULL

Fungal	NULL
metabolite	NULL
FR901228	NULL
inhibits	NULL
c-myc	NULL
and	NULL
Fas	NULL
ligand	NULL
expression	NULL
.	NULL

Oncogene	NULL
,	NULL
In	NULL
press	NULL
.	NULL

6107	NULL
'01	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
jountwrut	NULL
{	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
;	NULL

